Disorder of Catecholamine Synthesis

👪

Inheritance

1

Autosomal recessive inheritance HP:0000007

Most well-characterized disorders in this umbrella are autosomal recessive, including DDC/AADC deficiency, TH deficiency, and recessive BH4-pathway disorders.

Autosomal recessive inheritance

Show evidence (2 references)

DOI:10.3390/genes15010134 SUPPORT Human Clinical

"Aromatic L-amino acid decarboxylase deficiency (AADCd) is a rare autosomal recessive neurometabolic disorder caused by AADC deficiency, an enzyme encoded by the DDC gene."

Supports autosomal recessive inheritance for AADC deficiency.

DOI:10.1002/mdc3.14157 SUPPORT Human Clinical

"Autosomal dominant GTPCH (adGTPCH) deficiency is the most common cause of dopa‐responsive dystonia (DRD), whereas the recessive form (arGTPCH) is an ultrarare and poorly characterized disorder with earlier and more complex presentation that may disrupt neurodevelopmental processes."

Supports recessive inheritance for arGTPCH deficiency.

◆

Subtypes

5

Aromatic L-amino acid decarboxylase deficiency MONDO:0012084

DDC-related AADC deficiency is an autosomal recessive neurometabolic disorder that impairs serotonin and dopamine biosynthesis and secondarily lowers norepinephrine and epinephrine.

Show evidence (1 reference)

DOI:10.3390/genes15010134 SUPPORT Human Clinical

"Aromatic L-amino acid decarboxylase deficiency (AADCd) is a rare autosomal recessive neurometabolic disorder caused by AADC deficiency, an enzyme encoded by the DDC gene."

Supports the DDC/AADC subtype and autosomal recessive etiology.

Tyrosine hydroxylase deficiency MONDO:0011551

TH deficiency is a biallelic TH disorder in the dopa-responsive dystonia spectrum, with phenotypes ranging from childhood dopa-responsive dystonia to infantile parkinsonism and encephalopathy.

Show evidence (1 reference)

DOI:10.1186/s12920-023-01510-1 SUPPORT Human Clinical

"Tyrosine hydroxylase deficiency (THD) is a rare movement disorder with broad phenotypic expression caused by bi-allelic mutations in the TH gene, which encode for tyrosine hydroxylase (TH) protein."

Supports TH deficiency as a genetic subtype.

Autosomal recessive GTP cyclohydrolase I deficiency MONDO:0100184

Recessive GCH1 deficiency disrupts tetrahydrobiopterin biosynthesis and causes a spectrum from early infantile encephalopathy to classical dopa-responsive dystonia.

Show evidence (1 reference)

DOI:10.1002/mdc3.14157 SUPPORT Human Clinical

"Three phenotypes were outlined: (1) early‐infantile encephalopathic phenotype with profound disability (24 of 45 patients), (2) dystonia‐parkinsonism phenotype with infantile/early‐childhood onset of developmental stagnation/regression preceding the emergence of movement disorder (7 of 45), and..."

Supports the phenotypic spectrum of recessive GCH1 deficiency.

Dopa-responsive dystonia due to sepiapterin reductase deficiency MONDO:0012994

SPR-related sepiapterin reductase deficiency is a BH4 biosynthesis disorder that can impair monoamine neurotransmitter synthesis.

Show evidence (1 reference)

DOI:10.1002/mgg3.2294 SUPPORT Human Clinical

"The BH4 metabolism, including de novo biosynthesis involved genes (i.e., guanosine 5′‐triphosphate cyclohydrolase I (GTPCH/GCH1), sepiapterin reductase (SR/SPR), 6‐pyruvoyl‐tetrahydropterin synthase (PTPS/PTS)), and two genes that play roles in cofactor regeneration pathway (i.e.,..."

Supports SPR as part of BH4 metabolism relevant to this group.

Hyperphenylalaninemia due to DNAJC12 deficiency MONDO:0044304

DNAJC12 pathogenic variants affect a co-chaperone for monoamine synthesis enzymes and can present with infantile dystonia, developmental delay, cognitive deficits, and young-onset parkinsonism.

Show evidence (1 reference)

DOI:10.1002/mds.29677 SUPPORT Human Clinical

"Recent studies show that pathogenic variants in DNAJC12 , a co‐chaperone for monoamine synthesis, may cause mild hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism, developmental delay and cognitive deficits."

Supports DNAJC12-related disease as a monoamine synthesis subtype.

⚙

Pathophysiology

5

AADC Enzymatic Deficiency

DDC pathogenic variants reduce aromatic L-amino acid decarboxylase activity, impairing conversion of L-DOPA to dopamine and 5-hydroxytryptophan to serotonin, with secondary reduction of norepinephrine and epinephrine.

DDC link

dopamine biosynthetic process link ↓ DECREASED

aromatic-L-amino-acid decarboxylase activity link ↓ DECREASED

Downstream

Combined Monoamine Deficiency

Low CSF homovanillic acid AADC deficiency lowers dopamine turnover to homovanillic acid in CSF.

Low CSF 5-hydroxyindoleacetic acid AADC deficiency lowers serotonin turnover to 5-hydroxyindoleacetic acid in CSF.

Elevated 3-O-methyldopa Blocked AADC flux increases the L-dopa metabolite 3-O-methyldopa.

Show evidence (2 references)

DOI:10.3390/genes15010134 SUPPORT Human Clinical

"Since the enzyme is involved in the biosynthesis of serotonin and dopamine, its deficiency determines the lack of these neurotransmitters, but also of norepinephrine and epinephrine."

Directly supports reduced serotonin, dopamine, norepinephrine, and epinephrine in AADC deficiency.

PMID:1357595 SUPPORT Human Clinical

"Concentrations of L-dopa, 3-methoxytyrosine, and 5-hydroxytryptophan were elevated in CSF, plasma, and urine."

Supports accumulation of upstream AADC substrates in human AADC deficiency.

TH Enzymatic Deficiency

Biallelic TH variants impair tyrosine hydroxylase, the enzyme that converts tyrosine toward L-DOPA, reducing dopamine biosynthesis and downstream catecholaminergic signaling.

TH link

dopamine biosynthetic process from tyrosine link ↓ DECREASED

tyrosine 3-monooxygenase activity link ↓ DECREASED

Downstream

Combined Monoamine Deficiency

Show evidence (1 reference)

DOI:10.1186/s12920-023-01510-1 SUPPORT Human Clinical

"Tyrosine hydroxylase deficiency (THD) is a rare movement disorder with broad phenotypic expression caused by bi-allelic mutations in the TH gene, which encode for tyrosine hydroxylase (TH) protein."

Supports TH variants as the molecular lesion in TH deficiency.

BH4 Cofactor Deficiency

Pathogenic variants in BH4 biosynthesis or regeneration genes impair tetrahydrobiopterin availability, reducing monoamine neurotransmitter synthesis and, in many subtypes, causing hyperphenylalaninemia.

GCH1 link PTS link QDPR link SPR link PCBD1 link

tetrahydrobiopterin biosynthetic process link ↓ DECREASED

Downstream

Combined Monoamine Deficiency

Hyperphenylalaninemia BH4-pathway defects produce non-PAH hyperphenylalaninemia.

Elevated blood phenylalanine BH4 biosynthesis and recycling defects produce non-PAH hyperphenylalaninemia.

Show evidence (2 references)

DOI:10.1002/mgg3.2294 SUPPORT Human Clinical

"The subsequent systemic hyperphenylalaninemia and monoamine neurotransmitter deficiency lead to neurological consequences."

Supports monoamine deficiency downstream of BH4-pathway defects.

DOI:10.1002/mdc3.14157 SUPPORT Human Clinical

"The GCH1 gene encodes the enzyme guanosine triphosphate cyclohydrolase I (GTPCH), which catalyzes the rate‐limiting step in the biosynthesis of tetrahydrobiopterin (BH4), a critical cofactor in the production of monoamine neurotransmitters."

Supports GCH1/BH4 biology in monoamine neurotransmitter production.

DNAJC12 Co-chaperone Dysfunction

DNAJC12 pathogenic variants impair a co-chaperone needed for monoamine synthesis enzyme function, producing hyperphenylalaninemia and central monoamine-related neurologic disease.

DNAJC12 link

Downstream

Combined Monoamine Deficiency DNAJC12 pathogenic variants affect a monoamine-synthesis co-chaperone.

Hyperphenylalaninemia DNAJC12-related monoamine synthesis disease can present with mild hyperphenylalaninemia.

Dystonia DNAJC12-related monoamine synthesis disease can include infantile dystonia.

Parkinsonism DNAJC12-related monoamine synthesis disease can include young-onset parkinsonism.

Show evidence (1 reference)

DOI:10.1002/mds.29677 SUPPORT Human Clinical

"It provides an overview of the structure of DNAJC12 protein, known genetic variants, domains, and binding partners, and elaborates on its role in monoamine synthesis, disease etiology, and pathogenesis."

Supports DNAJC12's role in monoamine synthesis pathogenesis.

Combined Monoamine Deficiency

Reduced synthesis of dopamine and other monoamines disrupts basal ganglia, motor, autonomic, and neurodevelopmental functions, producing movement disorders, developmental delay, and autonomic manifestations.

dopaminergic neuron link

catecholamine biosynthetic process link ↓ DECREASED

Downstream

Movement Disorder

Global Developmental Delay

Autonomic Dysfunction

Hypotonia Combined monoamine deficiency in AADC deficiency includes early hypotonia.

Oculogyric Crisis AADC-related monoamine deficiency includes oculogyric crises within its movement-disorder spectrum.

Dystonia Catecholamine and monoamine deficiency can manifest as dystonia.

Parkinsonism Recessive GCH1/BH4 cofactor deficiency and DNAJC12-related disease can manifest as parkinsonism.

Show evidence (2 references)

DOI:10.1002/jimd.12697 SUPPORT Human Clinical

"Inborn errors of neurotransmitter (NT) metabolism are a group of rare, heterogenous diseases with predominant neurological features, such as movement disorders, autonomic dysfunction, and developmental delay."

Supports the clinical consequences of inherited neurotransmitter metabolism defects.

DOI:10.1002/jimd.12649 SUPPORT Human Clinical

"The autosomal recessive defect of aromatic L‐amino acid decarboxylase (AADC) leads to a severe neurological disorder with manifestation in infancy due to a pronounced, combined deficiency of dopamine, serotonin and catecholamines."

Supports the reduced dopamine, serotonin, and catecholamine chemistry represented in this combined-deficiency node.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

8

Musculoskeletal 1

Hypotonia Hypotonia (HP:0001252)

Show evidence (2 references)

DOI:10.3390/genes15010134 SUPPORT Human Clinical

"Onset is early and the key signs are hypotonia, movement disorders (oculogyric crises, dystonia and hypokinesia), developmental delay and autonomic dysfunction."

Supports hypotonia in AADC deficiency.

DOI:10.1186/s12920-023-01510-1 SUPPORT Human Clinical

"A nearly 3-year-old boy was referred to pediatric neurology due to hypotonia, delayed motor milestones, and expressive speech delay."

Supports hypotonia in a TH deficiency case.

Nervous System 5

Movement Disorder Abnormality of movement (HP:0100022)

Show evidence (2 references)

DOI:10.1038/s41467-021-25515-5 SUPPORT Human Clinical

"Inherited disorders of neurotransmitter metabolism are rare neurodevelopmental diseases presenting with movement disorders and global developmental delay."

Registry study supports movement disorders as a broad phenotype.

DOI:10.3390/genes15010134 SUPPORT Human Clinical

"Onset is early and the key signs are hypotonia, movement disorders (oculogyric crises, dystonia and hypokinesia), developmental delay and autonomic dysfunction."

AADC-focused evidence supports movement disorders in a catecholamine synthesis subtype.

Global Developmental Delay Global developmental delay (HP:0001263)

Show evidence (1 reference)

DOI:10.1038/s41467-021-25515-5 SUPPORT Human Clinical

"Inherited disorders of neurotransmitter metabolism are rare neurodevelopmental diseases presenting with movement disorders and global developmental delay."

Registry study directly supports global developmental delay.

Parkinsonism Parkinsonism (HP:0001300)

Show evidence (2 references)

DOI:10.1002/mds.29677 SUPPORT Human Clinical

"Recent studies show that pathogenic variants in DNAJC12 , a co‐chaperone for monoamine synthesis, may cause mild hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism, developmental delay and cognitive deficits."

Supports parkinsonism in DNAJC12-related disease.

DOI:10.1002/mdc3.14157 SUPPORT Human Clinical

"Three phenotypes were outlined: (1) early‐infantile encephalopathic phenotype with profound disability (24 of 45 patients), (2) dystonia‐parkinsonism phenotype with infantile/early‐childhood onset of developmental stagnation/regression preceding the emergence of movement disorder (7 of 45), and..."

Supports a dystonia-parkinsonism subgroup in recessive GCH1 deficiency.

Dystonia Dystonia (HP:0001332)

Show evidence (3 references)

DOI:10.3390/genes15010134 SUPPORT Human Clinical

"Onset is early and the key signs are hypotonia, movement disorders (oculogyric crises, dystonia and hypokinesia), developmental delay and autonomic dysfunction."

Supports dystonia in AADC deficiency.

DOI:10.1002/mdc3.14157 SUPPORT Human Clinical

"Three phenotypes were outlined: (1) early‐infantile encephalopathic phenotype with profound disability (24 of 45 patients), (2) dystonia‐parkinsonism phenotype with infantile/early‐childhood onset of developmental stagnation/regression preceding the emergence of movement disorder (7 of 45), and..."

Supports dystonia-parkinsonism in recessive GCH1 deficiency.

DOI:10.1002/mds.29677 SUPPORT Human Clinical

"Recent studies show that pathogenic variants in DNAJC12 , a co‐chaperone for monoamine synthesis, may cause mild hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism, developmental delay and cognitive deficits."

Supports dystonia in DNAJC12-related disease.

Autonomic Dysfunction Abnormal autonomic nervous system physiology (HP:0012332)

Show evidence (1 reference)

DOI:10.3390/genes15010134 PARTIAL Human Clinical

"Onset is early and the key signs are hypotonia, movement disorders (oculogyric crises, dystonia and hypokinesia), developmental delay and autonomic dysfunction."

The abstract supports autonomic dysfunction generally; the phenotype is mapped to a broad HPO autonomic physiology term.

Other 2

Oculogyric Crisis Oculogyric crisis (HP:0010553)

Show evidence (1 reference)

DOI:10.3390/genes15010134 SUPPORT Human Clinical

"Onset is early and the key signs are hypotonia, movement disorders (oculogyric crises, dystonia and hypokinesia), developmental delay and autonomic dysfunction."

Supports oculogyric crises in AADC deficiency.

Hyperphenylalaninemia Hyperphenylalaninemia (HP:0004923)

Show evidence (2 references)

DOI:10.1002/mgg3.2294 SUPPORT Human Clinical

"Hyperphenylalaninemia (HPA) is a metabolic disorder classified into phenylalanine‐4‐hydroxylase (PAH) and non‐PAH deficiency."

Supports hyperphenylalaninemia in the BH4/non-PAH deficiency context.

DOI:10.1002/mds.29677 SUPPORT Human Clinical

"Recent studies show that pathogenic variants in DNAJC12 , a co‐chaperone for monoamine synthesis, may cause mild hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism, developmental delay and cognitive deficits."

Supports hyperphenylalaninemia in DNAJC12-related disease.

🧬

Genetic Associations

8

DDC biallelic pathogenic variants (Causative biallelic pathogenic variants)

Show evidence (1 reference)

DOI:10.3390/genes15010134 SUPPORT Human Clinical

"Aromatic L-amino acid decarboxylase deficiency (AADCd) is a rare autosomal recessive neurometabolic disorder caused by AADC deficiency, an enzyme encoded by the DDC gene."

Supports DDC as the causative gene for AADC deficiency.

TH biallelic pathogenic variants (Causative biallelic pathogenic variants)

Show evidence (1 reference)

DOI:10.1186/s12920-023-01510-1 SUPPORT Human Clinical

"Tyrosine hydroxylase deficiency (THD) is a rare movement disorder with broad phenotypic expression caused by bi-allelic mutations in the TH gene, which encode for tyrosine hydroxylase (TH) protein."

Supports biallelic TH variants in TH deficiency.

GCH1 pathogenic variants (Causative biallelic/recessive variants affecting GTP cyclohydrolase I and BH4 synthesis)

Show evidence (1 reference)

DOI:10.1002/mdc3.14157 SUPPORT Human Clinical

"The GCH1 gene encodes the enzyme guanosine triphosphate cyclohydrolase I (GTPCH), which catalyzes the rate‐limiting step in the biosynthesis of tetrahydrobiopterin (BH4), a critical cofactor in the production of monoamine neurotransmitters."

Supports GCH1 as the BH4 biosynthesis gene underlying GTP cyclohydrolase I deficiency.

PTS pathogenic variants (Causative variants affecting 6-pyruvoyltetrahydropterin synthase)

Show evidence (1 reference)

DOI:10.1002/mgg3.2294 SUPPORT Human Clinical

"We successfully identified six mutant alleles in BH4‐deficiency‐associated genes, including three novel mutations: one in QDPR, one in PTS, and one in the PCBD1 gene, thus giving a definite diagnosis to these patients."

Supports PTS mutant alleles in human BH4 deficiency.

QDPR pathogenic variants (Causative variants affecting dihydropteridine reductase)

Show evidence (1 reference)

DOI:10.1002/mgg3.2294 SUPPORT Human Clinical

"We successfully identified six mutant alleles in BH4‐deficiency‐associated genes, including three novel mutations: one in QDPR, one in PTS, and one in the PCBD1 gene, thus giving a definite diagnosis to these patients."

Supports QDPR mutant alleles in human BH4 deficiency.

SPR pathogenic variants (Causative variants affecting sepiapterin reductase)

Show evidence (1 reference)

DOI:10.1002/mgg3.2294 SUPPORT Human Clinical

"The latter is produced by mutations in genes involved in the tetrahydrobiopterin (BH4) biosynthesis pathway and DNAJC12 pathogenetic variants. The BH4 metabolism, including de novo biosynthesis involved genes (i.e., guanosine 5′‐triphosphate cyclohydrolase I (GTPCH/GCH1), sepiapterin reductase..."

Supports SPR as a BH4 biosynthesis gene whose mutation can produce the non-PAH hyperphenylalaninemia/BH4-deficiency group.

PCBD1 pathogenic variants (Causative variants affecting pterin-4 alpha-carbinolamine dehydratase)

Show evidence (1 reference)

DOI:10.1002/mgg3.2294 SUPPORT Human Clinical

"We successfully identified six mutant alleles in BH4‐deficiency‐associated genes, including three novel mutations: one in QDPR, one in PTS, and one in the PCBD1 gene, thus giving a definite diagnosis to these patients."

Supports PCBD1 mutant alleles in human BH4 deficiency.

DNAJC12 pathogenic variants (Pathogenic variants affecting monoamine synthesis co-chaperone function)

Show evidence (1 reference)

DOI:10.1002/mds.29677 SUPPORT Human Clinical

"Recent studies show that pathogenic variants in DNAJC12 , a co‐chaperone for monoamine synthesis, may cause mild hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism, developmental delay and cognitive deficits."

Supports DNAJC12 pathogenic variants as disease-causing.

💊

Treatments

5

Carbidopa-levodopa

Action: Pharmacotherapy NCIT:C15986

Agent: levodopa ↗

Carbidopa-levodopa can improve dopamine-responsive manifestations in TH deficiency and related dopa-responsive dystonia phenotypes.

Mechanism Target:

BYPASSES TH Enzymatic Deficiency

Target Phenotypes: Movement disorder ↗

Show evidence (2 references)

DOI:10.1186/s12920-023-01510-1 SUPPORT Human Clinical

"Some patients with THD have improvement in dystonia with carbidopa–levodopa, a synthetic form of dopamine typically used in Parkinson’s disease, and are considered to have dopa-responsive THD."

Supports carbidopa-levodopa for dopa-responsive TH deficiency.

DOI:10.1186/s12920-023-01510-1 SUPPORT Human Clinical

"The child was treated with carbidopa–levodopa with an excellent response, resulting in improved balance, fewer falls, and improved ability to jump, run and climb stairs."

Case report supports clinical improvement with carbidopa-levodopa.

AADC gene therapy

Action: gene therapy MAXO:0001001

AAV2-based gene supplementation with eladocagene exuparvovec or related hAADC vectors is a disease-directed therapy for AADC deficiency.

Mechanism Target:

RESTORES AADC Enzymatic Deficiency

Show evidence (2 references)

DOI:10.1002/jimd.12649 SUPPORT Human Clinical

"Recently, the putaminally‐delivered construct, Eladocagene exuparvovec has been approved by the European Medicines Agency and by the British Medicines and Healthcare products Regulatory Agency."

Supports eladocagene exuparvovec as an approved gene therapy for AADC deficiency.

DOI:10.1002/jimd.12697 SUPPORT Human Clinical

"Along with the recent European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA) approval of an AAV2 gene supplementation therapy for AADC deficiency, promising efficacy and safety profiles can be achieved in this group of diseases."

Supports AAV2 gene supplementation therapy for AADC deficiency.

Sapropterin/BH4 supplementation

Action: Pharmacotherapy NCIT:C15986

Agent: sapropterin ↗

Sapropterin, a synthetic tetrahydrobiopterin analog, can be used to reduce blood phenylalanine in BH4-responsive hyperphenylalaninemia; for this umbrella entry it targets hyperphenylalaninemia caused by BH4-pathway defects.

Mechanism Target:

RESTORES BH4 Cofactor Deficiency

Target Phenotypes: Hyperphenylalaninemia ↗

Show evidence (2 references)

DOI:10.1002/mgg3.2294 PARTIAL Human Clinical

"The latter is produced by mutations in genes involved in the tetrahydrobiopterin (BH4) biosynthesis pathway and DNAJC12 pathogenetic variants."

Supports BH4-pathway defects as causes of non-PAH hyperphenylalaninemia in this disorder group.

PMID:6119011 SUPPORT Human Clinical

"Under BH4 therapy (16 mg daily), the dopamine values increased about twice, serotonin threefold and the phenylalanine blood concentration normalized to 1-1.5 mg/dl."

Directly supports BH4 cofactor replacement in dihydrobiopterin synthetase deficiency, with improved monoamine metabolites and normalized phenylalanine.

AADC symptomatic pharmacotherapy

Action: Pharmacotherapy NCIT:C15986

Agent: pyridoxine ↗

Conventional symptomatic regimens for AADC deficiency may include vitamin B6, dopamine agonists, and monoamine oxidase inhibitors, although responses are variable and often incomplete.

Mechanism Target:

MODULATES AADC Enzymatic Deficiency

Target Phenotypes: Movement disorder ↗

Show evidence (2 references)

PMID:19172410 SUPPORT Human Clinical

"Drug regimes consisted of vitamin B6, dopamine agonists, MAO inhibitors and anticholinergics in different combinations."

Supports vitamin B6, dopamine agonists, and MAO inhibitors as symptomatic pharmacotherapies used in AADC deficiency.

PMID:19172410 PARTIAL Human Clinical

"No patient achieved a complete recovery from neurological symptoms, but partial improvement of mobility and mood could be achieved in some."

Captures the limited and variable response to conventional symptomatic pharmacotherapy.

Post-gene-therapy rehabilitation

Action: physical therapy MAXO:0000011

Rehabilitation after AADC gene therapy is recommended to help patients translate new motor capacity into functional gains.

Target Phenotypes: Motor delay ↗

Show evidence (2 references)

DOI:10.1186/s13023-024-03019-x SUPPORT Other

"The approval of eladocagene exuparvovec, a gene therapy for AADC deficiency with demonstrated efficacy for motor improvements, now expands the range of motor outcomes possible for patients with this disorder."

Supports rehabilitation needs after motor improvement from gene therapy.

DOI:10.1186/s13023-024-03019-x SUPPORT Other

"Therefore, we highlight specific rehabilitative needs of patients following gene therapy and propose a set of recommendations for the post-treatment period based on collective experiences of therapists, physicians, and caregivers treating and caring for patients with AADC deficiency who have..."

Supports post-treatment rehabilitation recommendations.

🔬

Biochemical Markers

5

Dopamine and catecholamine deficiency (DECREASED)

Context: AADC deficiency causes combined deficiency of dopamine, serotonin, and catecholamines; other catecholamine synthesis disorders impair overlapping monoamine pathways.

Pathograph Readouts

Readout Of Combined Monoamine Deficiency Negative Diagnostic

Low dopamine and catecholamine metabolites report reduced central monoamine synthesis.

Show evidence (1 reference)

DOI:10.1002/jimd.12649 SUPPORT Human Clinical

"The autosomal recessive defect of aromatic L‐amino acid decarboxylase (AADC) leads to a severe neurological disorder with manifestation in infancy due to a pronounced, combined deficiency of dopamine, serotonin and catecholamines."

Supports combined dopamine, serotonin, and catecholamine deficiency in AADC deficiency.

Elevated blood phenylalanine (INCREASED)

Context: BH4 biosynthesis or regeneration defects and DNAJC12-related disease can present with hyperphenylalaninemia alongside monoamine neurotransmitter deficiency.

Pathograph Readouts

Readout Of BH4 Cofactor Deficiency Positive Diagnostic

Elevated blood phenylalanine reports impaired BH4-dependent phenylalanine handling.

Show evidence (1 reference)

DOI:10.1002/mgg3.2294 SUPPORT Human Clinical

"The subsequent systemic hyperphenylalaninemia and monoamine neurotransmitter deficiency lead to neurological consequences."

Supports hyperphenylalaninemia plus monoamine neurotransmitter deficiency.

Low CSF homovanillic acid (DECREASED)

Context: Low CSF homovanillic acid reflects deficient dopamine synthesis and is part of the characteristic AADC deficiency neurotransmitter profile.

Pathograph Readouts

Readout Of AADC Enzymatic Deficiency Negative Diagnostic

Low CSF HVA reports impaired AADC-dependent dopamine production.

Readout Of Combined Monoamine Deficiency Negative Diagnostic

Low CSF HVA is a dopamine-metabolite component of combined monoamine deficiency.

Show evidence (1 reference)

PMID:19172410 SUPPORT Human Clinical

"In CSF all patients revealed the pattern typical of AADC with decreased concentrations of homovanillic and 5-hydroxyindoleacetic acid and elevated concentration of 3-ortho-methyldopa."

Supports decreased CSF homovanillic acid as part of the AADC biochemical profile.

Low CSF 5-hydroxyindoleacetic acid (DECREASED)

Context: Low CSF 5-hydroxyindoleacetic acid reflects deficient serotonin synthesis in AADC deficiency.

Pathograph Readouts

Readout Of AADC Enzymatic Deficiency Negative Diagnostic

Low CSF 5-HIAA reports impaired AADC-dependent serotonin production.

Readout Of Combined Monoamine Deficiency Negative Diagnostic

Low CSF 5-HIAA is a serotonin-metabolite component of combined monoamine deficiency.

Show evidence (1 reference)

PMID:19172410 SUPPORT Human Clinical

"In CSF all patients revealed the pattern typical of AADC with decreased concentrations of homovanillic and 5-hydroxyindoleacetic acid and elevated concentration of 3-ortho-methyldopa."

Supports decreased CSF 5-hydroxyindoleacetic acid as part of the AADC biochemical profile.

Elevated 3-O-methyldopa (INCREASED)

Context: Elevated 3-O-methyldopa in CSF or dried blood spots is a substrate-diversion marker for AADC deficiency and can support newborn screening.

Pathograph Readouts

Readout Of AADC Enzymatic Deficiency Positive Diagnostic

Elevated 3-OMD reports blocked AADC flux from L-dopa to dopamine.

Show evidence (1 reference)

PMID:37635029 SUPPORT Human Clinical

"We demonstrated that an elevated concentration of L-dopa metabolite 3-O-methyldopa (3-OMD) in dried blood spots could be integrated into a newborn screening program to detect AADC deficiency."

Supports elevated DBS 3-O-methyldopa as a diagnostic AADC deficiency biomarker.

🔬

Clinical Trials

4

NCT01395641 PHASE_I COMPLETED

Phase I/II AAV2-hAADC trial for AADC deficiency.

Show evidence (1 reference)

clinicaltrials:NCT01395641 SUPPORT Human Clinical

"This Phase I/II trial is to prove the efficacy and safety of AAV2-hAADC to treat patients with AADC deficiency."

Supports this trial as AADC gene therapy research.

NCT04903288 PHASE_II COMPLETED

Eladocagene exuparvovec trial using the SmartFlow MR-compatible cannula.

Show evidence (1 reference)

clinicaltrials:NCT04903288 SUPPORT Human Clinical

"The long-term extension phase is designed to capture long-term safety and efficacy data from participants treated with eladocagene exuparvovec."

Supports long-term safety and efficacy follow-up for eladocagene exuparvovec.

NCT05765981 PHASE_I RECRUITING

Early-phase VGN-R09b AAV9-hAADC intra-striatum trial for AADC deficiency.

Show evidence (1 reference)

clinicaltrials:NCT05765981 SUPPORT Human Clinical

"This early Phase trial is to prove the safety and efficacy of VGN-R09b to treat patients with AADC deficiency."

Supports VGN-R09b as an AADC deficiency gene therapy trial.

NCT02852213 PHASE_I RECRUITING

AAV2-hAADC trial delivering vector to midbrain targets in pediatric AADC deficiency.

Show evidence (1 reference)

clinicaltrials:NCT02852213 SUPPORT Human Clinical

"The overall objective of this study is to determine the safety and efficacy of AAV2-hAADC delivered to the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) in children with aromatic L-amino acid decarboxylase (AADC) deficiency."

Supports AAV2-hAADC midbrain delivery as an AADC deficiency trial.

{ }

Source YAML

click to show

name: Disorder of Catecholamine Synthesis
creation_date: "2026-05-08T13:18:01Z"
updated_date: "2026-05-20T23:49:25Z"
category: Genetic
parents:
- Inborn Disorder of Neurotransmitter Metabolism and Transport
- Inborn Error of Metabolism
disease_term:
  preferred_term: disorder of catecholamine synthesis
  term:
    id: MONDO:0017759
    label: disorder of catecholamine synthesis
synonyms:
- Inherited disorder of catecholamine biosynthesis
- Inherited disorder of biogenic amine synthesis
- Monoamine neurotransmitter synthesis disorder
description: >-
  Disorder of catecholamine synthesis is an umbrella grouping for rare inherited
  disorders that impair dopamine, norepinephrine, epinephrine, and often
  serotonin synthesis through defects in core biosynthetic enzymes, BH4 cofactor
  metabolism, or monoamine-enzyme chaperone function. The group includes
  aromatic L-amino acid decarboxylase deficiency, tyrosine hydroxylase
  deficiency, recessive GTP cyclohydrolase I deficiency and related BH4
  biosynthesis or recycling disorders, sepiapterin reductase deficiency, and
  DNAJC12-related monoamine synthesis disease.
has_subtypes:
- name: Aromatic L-amino acid decarboxylase deficiency
  display_name: Aromatic L-amino acid decarboxylase deficiency
  subtype_term:
    preferred_term: aromatic L-amino acid decarboxylase deficiency
    term:
      id: MONDO:0012084
      label: aromatic L-amino acid decarboxylase deficiency
  description: >-
    DDC-related AADC deficiency is an autosomal recessive neurometabolic
    disorder that impairs serotonin and dopamine biosynthesis and secondarily
    lowers norepinephrine and epinephrine.
  evidence:
  - reference: DOI:10.3390/genes15010134
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aromatic L-amino acid decarboxylase deficiency (AADCd) is a rare
      autosomal recessive neurometabolic disorder caused by AADC deficiency, an
      enzyme encoded by the DDC gene.
    explanation: Supports the DDC/AADC subtype and autosomal recessive etiology.
- name: Tyrosine hydroxylase deficiency
  display_name: Tyrosine hydroxylase deficiency
  subtype_term:
    preferred_term: TH-deficient dopa-responsive dystonia
    term:
      id: MONDO:0011551
      label: TH-deficient dopa-responsive dystonia
  description: >-
    TH deficiency is a biallelic TH disorder in the dopa-responsive dystonia
    spectrum, with phenotypes ranging from childhood dopa-responsive dystonia
    to infantile parkinsonism and encephalopathy.
  evidence:
  - reference: DOI:10.1186/s12920-023-01510-1
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tyrosine hydroxylase deficiency (THD) is a rare movement disorder with
      broad phenotypic expression caused by bi-allelic mutations in the TH gene,
      which encode for tyrosine hydroxylase (TH) protein.
    explanation: Supports TH deficiency as a genetic subtype.
- name: Autosomal recessive GTP cyclohydrolase I deficiency
  display_name: Autosomal recessive GTP cyclohydrolase I deficiency
  subtype_term:
    preferred_term: GTP cyclohydrolase I deficiency
    term:
      id: MONDO:0100184
      label: GTP cyclohydrolase I deficiency
  description: >-
    Recessive GCH1 deficiency disrupts tetrahydrobiopterin biosynthesis and
    causes a spectrum from early infantile encephalopathy to classical
    dopa-responsive dystonia.
  evidence:
  - reference: DOI:10.1002/mdc3.14157
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three phenotypes were outlined: (1) early‐infantile encephalopathic
      phenotype with profound disability (24 of 45 patients), (2)
      dystonia‐parkinsonism phenotype with infantile/early‐childhood onset of
      developmental stagnation/regression preceding the emergence of movement
      disorder (7 of 45), and (3) late‐onset DRD phenotype (14 of 45).
    explanation: Supports the phenotypic spectrum of recessive GCH1 deficiency.
- name: Sepiapterin reductase deficiency
  display_name: Dopa-responsive dystonia due to sepiapterin reductase deficiency
  subtype_term:
    preferred_term: dopa-responsive dystonia due to sepiapterin reductase deficiency
    term:
      id: MONDO:0012994
      label: dopa-responsive dystonia due to sepiapterin reductase deficiency
  description: >-
    SPR-related sepiapterin reductase deficiency is a BH4 biosynthesis disorder
    that can impair monoamine neurotransmitter synthesis.
  evidence:
  - reference: DOI:10.1002/mgg3.2294
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The BH4 metabolism, including de novo biosynthesis involved genes (i.e.,
      guanosine 5′‐triphosphate cyclohydrolase I (GTPCH/GCH1), sepiapterin
      reductase (SR/SPR), 6‐pyruvoyl‐tetrahydropterin synthase (PTPS/PTS)), and
      two genes that play roles in cofactor regeneration pathway (i.e.,
      dihydropteridine reductase (DHPR/QDPR) and
      pterin‐4α‐carbinolamine dehydratase (PCD/PCBD1)).
    explanation: Supports SPR as part of BH4 metabolism relevant to this group.
- name: DNAJC12-related monoamine synthesis disorder
  display_name: Hyperphenylalaninemia due to DNAJC12 deficiency
  subtype_term:
    preferred_term: hyperphenylalaninemia due to DNAJC12 deficiency
    term:
      id: MONDO:0044304
      label: hyperphenylalaninemia due to DNAJC12 deficiency
  description: >-
    DNAJC12 pathogenic variants affect a co-chaperone for monoamine synthesis
    enzymes and can present with infantile dystonia, developmental delay,
    cognitive deficits, and young-onset parkinsonism.
  evidence:
  - reference: DOI:10.1002/mds.29677
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recent studies show that pathogenic variants in
                    DNAJC12
                    , a co‐chaperone for monoamine synthesis, may cause mild
      hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism,
      developmental delay and cognitive deficits.
    explanation: Supports DNAJC12-related disease as a monoamine synthesis subtype.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Most well-characterized disorders in this umbrella are autosomal recessive,
    including DDC/AADC deficiency, TH deficiency, and recessive BH4-pathway
    disorders.
  evidence:
  - reference: DOI:10.3390/genes15010134
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aromatic L-amino acid decarboxylase deficiency (AADCd) is a rare
      autosomal recessive neurometabolic disorder caused by AADC deficiency, an
      enzyme encoded by the DDC gene.
    explanation: Supports autosomal recessive inheritance for AADC deficiency.
  - reference: DOI:10.1002/mdc3.14157
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Autosomal dominant GTPCH (adGTPCH) deficiency is the most common cause of
      dopa‐responsive dystonia (DRD), whereas the recessive form (arGTPCH) is an
      ultrarare and poorly characterized disorder with earlier and more complex
      presentation that may disrupt neurodevelopmental processes.
    explanation: Supports recessive inheritance for arGTPCH deficiency.
pathophysiology:
- name: AADC Enzymatic Deficiency
  description: >-
    DDC pathogenic variants reduce aromatic L-amino acid decarboxylase activity,
    impairing conversion of L-DOPA to dopamine and 5-hydroxytryptophan to
    serotonin, with secondary reduction of norepinephrine and epinephrine.
  genes:
  - preferred_term: DDC
    term:
      id: hgnc:2719
      label: DDC
  molecular_functions:
  - preferred_term: aromatic-L-amino-acid decarboxylase activity
    term:
      id: GO:0004058
      label: aromatic-L-amino-acid decarboxylase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: dopamine biosynthetic process
    term:
      id: GO:0042416
      label: dopamine biosynthetic process
    modifier: DECREASED
  chemical_entities:
  - preferred_term: dopamine
    term:
      id: CHEBI:18243
      label: dopamine
    modifier: DECREASED
  - preferred_term: serotonin
    term:
      id: CHEBI:28790
      label: serotonin
    modifier: DECREASED
  - preferred_term: L-dopa
    term:
      id: CHEBI:15765
      label: L-dopa
    modifier: INCREASED
  - preferred_term: 3-O-methyldopa
    term:
      id: CHEBI:82913
      label: 3-O-methyldopa
    modifier: INCREASED
  downstream:
  - target: Combined Monoamine Deficiency
    causal_link_type: DIRECT
  - target: Low CSF homovanillic acid
    description: AADC deficiency lowers dopamine turnover to homovanillic acid in CSF.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19172410
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        In CSF all patients revealed the pattern typical of AADC with decreased
        concentrations of homovanillic and 5-hydroxyindoleacetic acid and
        elevated concentration of 3-ortho-methyldopa.
      explanation: Supports low CSF homovanillic acid as a biochemical consequence of AADC deficiency.
  - target: Low CSF 5-hydroxyindoleacetic acid
    description: AADC deficiency lowers serotonin turnover to 5-hydroxyindoleacetic acid in CSF.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:19172410
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        In CSF all patients revealed the pattern typical of AADC with decreased
        concentrations of homovanillic and 5-hydroxyindoleacetic acid and
        elevated concentration of 3-ortho-methyldopa.
      explanation: Supports low CSF 5-hydroxyindoleacetic acid as a biochemical consequence of AADC deficiency.
  - target: Elevated 3-O-methyldopa
    description: Blocked AADC flux increases the L-dopa metabolite 3-O-methyldopa.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:37635029
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We demonstrated that an elevated concentration of L-dopa metabolite
        3-O-methyldopa (3-OMD) in dried blood spots could be integrated into a
        newborn screening program to detect AADC deficiency.
      explanation: Supports elevated 3-O-methyldopa as a direct AADC-deficiency biochemical readout.
  evidence:
  - reference: DOI:10.3390/genes15010134
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Since the enzyme is involved in the biosynthesis of serotonin and
      dopamine, its deficiency determines the lack of these neurotransmitters,
      but also of norepinephrine and epinephrine.
    explanation: Directly supports reduced serotonin, dopamine, norepinephrine, and epinephrine in AADC deficiency.
  - reference: PMID:1357595
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Concentrations of L-dopa, 3-methoxytyrosine, and 5-hydroxytryptophan were
      elevated in CSF, plasma, and urine.
    explanation: Supports accumulation of upstream AADC substrates in human AADC deficiency.
- name: TH Enzymatic Deficiency
  description: >-
    Biallelic TH variants impair tyrosine hydroxylase, the enzyme that converts
    tyrosine toward L-DOPA, reducing dopamine biosynthesis and downstream
    catecholaminergic signaling.
  genes:
  - preferred_term: TH
    term:
      id: hgnc:11782
      label: TH
  molecular_functions:
  - preferred_term: tyrosine 3-monooxygenase activity
    term:
      id: GO:0004511
      label: tyrosine 3-monooxygenase activity
    modifier: DECREASED
  biological_processes:
  - preferred_term: dopamine biosynthetic process from tyrosine
    term:
      id: GO:0006585
      label: dopamine biosynthetic process from tyrosine
    modifier: DECREASED
  downstream:
  - target: Combined Monoamine Deficiency
    causal_link_type: DIRECT
  evidence:
  - reference: DOI:10.1186/s12920-023-01510-1
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tyrosine hydroxylase deficiency (THD) is a rare movement disorder with
      broad phenotypic expression caused by bi-allelic mutations in the TH gene,
      which encode for tyrosine hydroxylase (TH) protein.
    explanation: Supports TH variants as the molecular lesion in TH deficiency.
- name: BH4 Cofactor Deficiency
  description: >-
    Pathogenic variants in BH4 biosynthesis or regeneration genes impair
    tetrahydrobiopterin availability, reducing monoamine neurotransmitter
    synthesis and, in many subtypes, causing hyperphenylalaninemia.
  genes:
  - preferred_term: GCH1
    term:
      id: hgnc:4193
      label: GCH1
  - preferred_term: PTS
    term:
      id: hgnc:9689
      label: PTS
  - preferred_term: QDPR
    term:
      id: hgnc:9752
      label: QDPR
  - preferred_term: SPR
    term:
      id: hgnc:11257
      label: SPR
  - preferred_term: PCBD1
    term:
      id: hgnc:8646
      label: PCBD1
  biological_processes:
  - preferred_term: tetrahydrobiopterin biosynthetic process
    term:
      id: GO:0006729
      label: tetrahydrobiopterin biosynthetic process
    modifier: DECREASED
  chemical_entities:
  - preferred_term: tetrahydrobiopterin
    term:
      id: CHEBI:15372
      label: 5,6,7,8-tetrahydrobiopterin
    modifier: DECREASED
  - preferred_term: L-phenylalanine
    term:
      id: CHEBI:58095
      label: L-phenylalanine zwitterion
    modifier: INCREASED
  downstream:
  - target: Combined Monoamine Deficiency
    causal_link_type: DIRECT
  - target: Hyperphenylalaninemia
    description: BH4-pathway defects produce non-PAH hyperphenylalaninemia.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.1002/mgg3.2294
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The subsequent systemic hyperphenylalaninemia and monoamine
        neurotransmitter deficiency lead to neurological consequences.
      explanation: Supports hyperphenylalaninemia as a direct systemic consequence of BH4-pathway defects.
  - target: Elevated blood phenylalanine
    description: BH4 biosynthesis and recycling defects produce non-PAH hyperphenylalaninemia.
    causal_link_type: DIRECT
    evidence:
    - reference: DOI:10.1002/mgg3.2294
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The subsequent systemic hyperphenylalaninemia and monoamine
        neurotransmitter deficiency lead to neurological consequences.
      explanation: Supports hyperphenylalaninemia downstream of BH4-pathway defects.
  evidence:
  - reference: DOI:10.1002/mgg3.2294
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The subsequent systemic hyperphenylalaninemia and monoamine
      neurotransmitter deficiency lead to neurological consequences.
    explanation: Supports monoamine deficiency downstream of BH4-pathway defects.
  - reference: DOI:10.1002/mdc3.14157
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The GCH1 gene encodes the enzyme guanosine triphosphate cyclohydrolase I
      (GTPCH), which catalyzes the rate‐limiting step in the biosynthesis of
      tetrahydrobiopterin (BH4), a critical cofactor in the production of
      monoamine neurotransmitters.
    explanation: Supports GCH1/BH4 biology in monoamine neurotransmitter production.
- name: DNAJC12 Co-chaperone Dysfunction
  description: >-
    DNAJC12 pathogenic variants impair a co-chaperone needed for monoamine
    synthesis enzyme function, producing hyperphenylalaninemia and central
    monoamine-related neurologic disease.
  genes:
  - preferred_term: DNAJC12
    term:
      id: hgnc:28908
      label: DNAJC12
  downstream:
  - target: Combined Monoamine Deficiency
    description: DNAJC12 pathogenic variants affect a monoamine-synthesis co-chaperone.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - impaired monoamine synthesis enzyme chaperoning
    evidence:
    - reference: DOI:10.1002/mds.29677
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Recent studies show that pathogenic variants in
                    DNAJC12
                    , a co‐chaperone for monoamine synthesis, may cause mild
        hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism,
        developmental delay and cognitive deficits.
      explanation: Supports DNAJC12 pathogenic variants as impairing monoamine synthesis through a co-chaperone mechanism.
  - target: Hyperphenylalaninemia
    description: DNAJC12-related monoamine synthesis disease can present with mild hyperphenylalaninemia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - DNAJC12 co-chaperone dysfunction
    evidence:
    - reference: DOI:10.1002/mds.29677
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Recent studies show that pathogenic variants in
                    DNAJC12
                    , a co‐chaperone for monoamine synthesis, may cause mild
        hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism,
        developmental delay and cognitive deficits.
      explanation: Supports hyperphenylalaninemia in DNAJC12-related disease.
  - target: Dystonia
    description: DNAJC12-related monoamine synthesis disease can include infantile dystonia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Combined Monoamine Deficiency
    evidence:
    - reference: DOI:10.1002/mds.29677
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Recent studies show that pathogenic variants in
                    DNAJC12
                    , a co‐chaperone for monoamine synthesis, may cause mild
        hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism,
        developmental delay and cognitive deficits.
      explanation: Supports infantile dystonia in DNAJC12-related disease.
  - target: Parkinsonism
    description: DNAJC12-related monoamine synthesis disease can include young-onset parkinsonism.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Combined Monoamine Deficiency
    evidence:
    - reference: DOI:10.1002/mds.29677
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Recent studies show that pathogenic variants in
                    DNAJC12
                    , a co‐chaperone for monoamine synthesis, may cause mild
        hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism,
        developmental delay and cognitive deficits.
      explanation: Supports young-onset parkinsonism in DNAJC12-related disease.
  evidence:
  - reference: DOI:10.1002/mds.29677
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It provides an overview of the structure of DNAJC12 protein, known genetic
      variants, domains, and binding partners, and elaborates on its role in
      monoamine synthesis, disease etiology, and pathogenesis.
    explanation: Supports DNAJC12's role in monoamine synthesis pathogenesis.
- name: Combined Monoamine Deficiency
  description: >-
    Reduced synthesis of dopamine and other monoamines disrupts basal ganglia,
    motor, autonomic, and neurodevelopmental functions, producing movement
    disorders, developmental delay, and autonomic manifestations.
  cell_types:
  - preferred_term: dopaminergic neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  biological_processes:
  - preferred_term: catecholamine biosynthetic process
    term:
      id: GO:0042423
      label: catecholamine biosynthetic process
    modifier: DECREASED
  chemical_entities:
  - preferred_term: dopamine
    term:
      id: CHEBI:18243
      label: dopamine
    modifier: DECREASED
  - preferred_term: serotonin
    term:
      id: CHEBI:28790
      label: serotonin
    modifier: DECREASED
  - preferred_term: noradrenaline
    term:
      id: CHEBI:18357
      label: (R)-noradrenaline
    modifier: DECREASED
  - preferred_term: adrenaline
    term:
      id: CHEBI:28918
      label: (R)-adrenaline
    modifier: DECREASED
  downstream:
  - target: Movement Disorder
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Global Developmental Delay
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Autonomic Dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  - target: Hypotonia
    description: Combined monoamine deficiency in AADC deficiency includes early hypotonia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: DOI:10.3390/genes15010134
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Onset is early and the key signs are hypotonia, movement disorders
        (oculogyric crises, dystonia and hypokinesia), developmental delay and
        autonomic dysfunction.
      explanation: Supports hypotonia as a clinical consequence in AADC-related monoamine deficiency.
  - target: Oculogyric Crisis
    description: AADC-related monoamine deficiency includes oculogyric crises within its movement-disorder spectrum.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: DOI:10.3390/genes15010134
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Onset is early and the key signs are hypotonia, movement disorders
        (oculogyric crises, dystonia and hypokinesia), developmental delay and
        autonomic dysfunction.
      explanation: Supports oculogyric crises downstream of AADC-related monoamine deficiency.
  - target: Dystonia
    description: Catecholamine and monoamine deficiency can manifest as dystonia.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: DOI:10.3390/genes15010134
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Onset is early and the key signs are hypotonia, movement disorders
        (oculogyric crises, dystonia and hypokinesia), developmental delay and
        autonomic dysfunction.
      explanation: Supports dystonia as part of the AADC-related monoamine-deficiency movement disorder.
    - reference: DOI:10.1002/mdc3.14157
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Three phenotypes were outlined: (1) early‐infantile encephalopathic
        phenotype with profound disability (24 of 45 patients), (2)
        dystonia‐parkinsonism phenotype with infantile/early‐childhood onset of
        developmental stagnation/regression preceding the emergence of movement
        disorder (7 of 45), and (3) late‐onset DRD phenotype (14 of 45).
      explanation: Supports dystonia-parkinsonism in recessive GCH1/BH4 cofactor deficiency.
  - target: Parkinsonism
    description: Recessive GCH1/BH4 cofactor deficiency and DNAJC12-related disease can manifest as parkinsonism.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    evidence:
    - reference: DOI:10.1002/mdc3.14157
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Three phenotypes were outlined: (1) early‐infantile encephalopathic
        phenotype with profound disability (24 of 45 patients), (2)
        dystonia‐parkinsonism phenotype with infantile/early‐childhood onset of
        developmental stagnation/regression preceding the emergence of movement
        disorder (7 of 45), and (3) late‐onset DRD phenotype (14 of 45).
      explanation: Supports parkinsonism in the dystonia-parkinsonism subgroup of recessive GCH1 deficiency.
    - reference: DOI:10.1002/mds.29677
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Recent studies show that pathogenic variants in
                    DNAJC12
                    , a co‐chaperone for monoamine synthesis, may cause mild
        hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism,
        developmental delay and cognitive deficits.
      explanation: Supports young-onset parkinsonism in DNAJC12-related monoamine synthesis disease.
  evidence:
  - reference: DOI:10.1002/jimd.12697
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Inborn errors of neurotransmitter (NT) metabolism are a group of rare,
      heterogenous diseases with predominant neurological features, such as
      movement disorders, autonomic dysfunction, and developmental delay.
    explanation: Supports the clinical consequences of inherited neurotransmitter metabolism defects.
  - reference: DOI:10.1002/jimd.12649
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The autosomal recessive defect of aromatic L‐amino acid decarboxylase
      (AADC) leads to a severe neurological disorder with manifestation in
      infancy due to a pronounced, combined deficiency of dopamine, serotonin
      and catecholamines.
    explanation: Supports the reduced dopamine, serotonin, and catecholamine chemistry represented in this combined-deficiency node.
phenotypes:
- category: Neurologic
  name: Movement Disorder
  description: >-
    Movement disorders are core features across inherited neurotransmitter and
    catecholamine synthesis disorders, including dystonia, hypokinesia,
    oculogyric crises, and parkinsonism depending on subtype.
  phenotype_term:
    preferred_term: Movement disorder
    term:
      id: HP:0100022
      label: Abnormality of movement
  evidence:
  - reference: DOI:10.1038/s41467-021-25515-5
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Inherited disorders of neurotransmitter metabolism are rare
      neurodevelopmental diseases presenting with movement disorders and global
      developmental delay.
    explanation: Registry study supports movement disorders as a broad phenotype.
  - reference: DOI:10.3390/genes15010134
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Onset is early and the key signs are hypotonia, movement disorders
      (oculogyric crises, dystonia and hypokinesia), developmental delay and
      autonomic dysfunction.
    explanation: AADC-focused evidence supports movement disorders in a catecholamine synthesis subtype.
- category: Neurologic
  name: Global Developmental Delay
  description: >-
    Global developmental delay is common in severe inherited neurotransmitter
    synthesis disorders and may accompany motor and autonomic phenotypes.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: DOI:10.1038/s41467-021-25515-5
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Inherited disorders of neurotransmitter metabolism are rare
      neurodevelopmental diseases presenting with movement disorders and global
      developmental delay.
    explanation: Registry study directly supports global developmental delay.
- category: Neurologic
  name: Hypotonia
  description: Hypotonia is an early motor feature in AADC deficiency and can occur in TH deficiency.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: DOI:10.3390/genes15010134
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Onset is early and the key signs are hypotonia, movement disorders
      (oculogyric crises, dystonia and hypokinesia), developmental delay and
      autonomic dysfunction.
    explanation: Supports hypotonia in AADC deficiency.
  - reference: DOI:10.1186/s12920-023-01510-1
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A nearly 3-year-old boy was referred to pediatric neurology due to
      hypotonia, delayed motor milestones, and expressive speech delay.
    explanation: Supports hypotonia in a TH deficiency case.
- category: Neurologic
  name: Oculogyric Crisis
  description: Oculogyric crises are part of the movement-disorder phenotype in AADC deficiency.
  phenotype_term:
    preferred_term: Oculogyric crisis
    term:
      id: HP:0010553
      label: Oculogyric crisis
  evidence:
  - reference: DOI:10.3390/genes15010134
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Onset is early and the key signs are hypotonia, movement disorders
      (oculogyric crises, dystonia and hypokinesia), developmental delay and
      autonomic dysfunction.
    explanation: Supports oculogyric crises in AADC deficiency.
- category: Neurologic
  name: Parkinsonism
  description: Parkinsonism can occur in TH deficiency, recessive GCH1 deficiency, and DNAJC12-related disease.
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
  evidence:
  - reference: DOI:10.1002/mds.29677
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recent studies show that pathogenic variants in
                    DNAJC12
                    , a co‐chaperone for monoamine synthesis, may cause mild
      hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism,
      developmental delay and cognitive deficits.
    explanation: Supports parkinsonism in DNAJC12-related disease.
  - reference: DOI:10.1002/mdc3.14157
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three phenotypes were outlined: (1) early‐infantile encephalopathic
      phenotype with profound disability (24 of 45 patients), (2)
      dystonia‐parkinsonism phenotype with infantile/early‐childhood onset of
      developmental stagnation/regression preceding the emergence of movement
      disorder (7 of 45), and (3) late‐onset DRD phenotype (14 of 45).
    explanation: Supports a dystonia-parkinsonism subgroup in recessive GCH1 deficiency.
- category: Neurologic
  name: Dystonia
  description: Dystonia is a core movement-disorder feature in AADC deficiency, recessive GCH1 deficiency, and DNAJC12-related disease.
  phenotype_term:
    preferred_term: Dystonia
    term:
      id: HP:0001332
      label: Dystonia
  evidence:
  - reference: DOI:10.3390/genes15010134
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Onset is early and the key signs are hypotonia, movement disorders
      (oculogyric crises, dystonia and hypokinesia), developmental delay and
      autonomic dysfunction.
    explanation: Supports dystonia in AADC deficiency.
  - reference: DOI:10.1002/mdc3.14157
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Three phenotypes were outlined: (1) early‐infantile encephalopathic
      phenotype with profound disability (24 of 45 patients), (2)
      dystonia‐parkinsonism phenotype with infantile/early‐childhood onset of
      developmental stagnation/regression preceding the emergence of movement
      disorder (7 of 45), and (3) late‐onset DRD phenotype (14 of 45).
    explanation: Supports dystonia-parkinsonism in recessive GCH1 deficiency.
  - reference: DOI:10.1002/mds.29677
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recent studies show that pathogenic variants in
                    DNAJC12
                    , a co‐chaperone for monoamine synthesis, may cause mild
      hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism,
      developmental delay and cognitive deficits.
    explanation: Supports dystonia in DNAJC12-related disease.
- category: Autonomic
  name: Autonomic Dysfunction
  description: Autonomic dysfunction is a key clinical feature in AADC deficiency.
  phenotype_term:
    preferred_term: Autonomic dysfunction
    term:
      id: HP:0012332
      label: Abnormal autonomic nervous system physiology
  evidence:
  - reference: DOI:10.3390/genes15010134
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Onset is early and the key signs are hypotonia, movement disorders
      (oculogyric crises, dystonia and hypokinesia), developmental delay and
      autonomic dysfunction.
    explanation: >-
      The abstract supports autonomic dysfunction generally; the phenotype is
      mapped to a broad HPO autonomic physiology term.
- category: Biochemical
  name: Hyperphenylalaninemia
  description: Hyperphenylalaninemia occurs in many BH4-pathway and DNAJC12-related disorders.
  phenotype_term:
    preferred_term: Hyperphenylalaninemia
    term:
      id: HP:0004923
      label: Hyperphenylalaninemia
  evidence:
  - reference: DOI:10.1002/mgg3.2294
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Hyperphenylalaninemia (HPA) is a metabolic disorder classified into
      phenylalanine‐4‐hydroxylase (PAH) and non‐PAH deficiency.
    explanation: Supports hyperphenylalaninemia in the BH4/non-PAH deficiency context.
  - reference: DOI:10.1002/mds.29677
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recent studies show that pathogenic variants in
                    DNAJC12
                    , a co‐chaperone for monoamine synthesis, may cause mild
      hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism,
      developmental delay and cognitive deficits.
    explanation: Supports hyperphenylalaninemia in DNAJC12-related disease.
biochemical:
- name: Dopamine and catecholamine deficiency
  presence: DECREASED
  context: >-
    AADC deficiency causes combined deficiency of dopamine, serotonin, and
    catecholamines; other catecholamine synthesis disorders impair overlapping
    monoamine pathways.
  biomarker_term:
    preferred_term: dopamine
    term:
      id: CHEBI:18243
      label: dopamine
  readouts:
  - target: Combined Monoamine Deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Low dopamine and catecholamine metabolites report reduced central monoamine synthesis.
  evidence:
  - reference: DOI:10.1002/jimd.12649
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The autosomal recessive defect of aromatic L‐amino acid decarboxylase
      (AADC) leads to a severe neurological disorder with manifestation in
      infancy due to a pronounced, combined deficiency of dopamine, serotonin
      and catecholamines.
    explanation: Supports combined dopamine, serotonin, and catecholamine deficiency in AADC deficiency.
- name: Elevated blood phenylalanine
  presence: INCREASED
  context: >-
    BH4 biosynthesis or regeneration defects and DNAJC12-related disease can
    present with hyperphenylalaninemia alongside monoamine neurotransmitter
    deficiency.
  biomarker_term:
    preferred_term: L-phenylalanine
    term:
      id: CHEBI:58095
      label: L-phenylalanine zwitterion
  readouts:
  - target: BH4 Cofactor Deficiency
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated blood phenylalanine reports impaired BH4-dependent phenylalanine handling.
  evidence:
  - reference: DOI:10.1002/mgg3.2294
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The subsequent systemic hyperphenylalaninemia and monoamine
      neurotransmitter deficiency lead to neurological consequences.
    explanation: Supports hyperphenylalaninemia plus monoamine neurotransmitter deficiency.
- name: Low CSF homovanillic acid
  presence: DECREASED
  context: >-
    Low CSF homovanillic acid reflects deficient dopamine synthesis and is part
    of the characteristic AADC deficiency neurotransmitter profile.
  biomarker_term:
    preferred_term: homovanillic acid
    term:
      id: CHEBI:545959
      label: homovanillic acid
  readouts:
  - target: AADC Enzymatic Deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Low CSF HVA reports impaired AADC-dependent dopamine production.
  - target: Combined Monoamine Deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Low CSF HVA is a dopamine-metabolite component of combined monoamine deficiency.
  evidence:
  - reference: PMID:19172410
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In CSF all patients revealed the pattern typical of AADC with decreased
      concentrations of homovanillic and 5-hydroxyindoleacetic acid and
      elevated concentration of 3-ortho-methyldopa.
    explanation: Supports decreased CSF homovanillic acid as part of the AADC biochemical profile.
- name: Low CSF 5-hydroxyindoleacetic acid
  presence: DECREASED
  context: >-
    Low CSF 5-hydroxyindoleacetic acid reflects deficient serotonin synthesis
    in AADC deficiency.
  biomarker_term:
    preferred_term: 5-hydroxyindoleacetic acid
    term:
      id: CHEBI:27823
      label: (5-hydroxyindol-3-yl)acetic acid
  readouts:
  - target: AADC Enzymatic Deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Low CSF 5-HIAA reports impaired AADC-dependent serotonin production.
  - target: Combined Monoamine Deficiency
    relationship: READOUT_OF
    direction: NEGATIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Low CSF 5-HIAA is a serotonin-metabolite component of combined monoamine deficiency.
  evidence:
  - reference: PMID:19172410
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In CSF all patients revealed the pattern typical of AADC with decreased
      concentrations of homovanillic and 5-hydroxyindoleacetic acid and
      elevated concentration of 3-ortho-methyldopa.
    explanation: Supports decreased CSF 5-hydroxyindoleacetic acid as part of the AADC biochemical profile.
- name: Elevated 3-O-methyldopa
  presence: INCREASED
  context: >-
    Elevated 3-O-methyldopa in CSF or dried blood spots is a substrate-diversion
    marker for AADC deficiency and can support newborn screening.
  biomarker_term:
    preferred_term: 3-O-methyldopa
    term:
      id: CHEBI:82913
      label: 3-O-methyldopa
  readouts:
  - target: AADC Enzymatic Deficiency
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Elevated 3-OMD reports blocked AADC flux from L-dopa to dopamine.
  evidence:
  - reference: PMID:37635029
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We demonstrated that an elevated concentration of L-dopa metabolite
      3-O-methyldopa (3-OMD) in dried blood spots could be integrated into a
      newborn screening program to detect AADC deficiency.
    explanation: Supports elevated DBS 3-O-methyldopa as a diagnostic AADC deficiency biomarker.
genetic:
- name: DDC biallelic pathogenic variants
  gene_term:
    preferred_term: DDC
    term:
      id: hgnc:2719
      label: DDC
  association: Causative biallelic pathogenic variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: Aromatic L-amino acid decarboxylase deficiency
  evidence:
  - reference: DOI:10.3390/genes15010134
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Aromatic L-amino acid decarboxylase deficiency (AADCd) is a rare
      autosomal recessive neurometabolic disorder caused by AADC deficiency, an
      enzyme encoded by the DDC gene.
    explanation: Supports DDC as the causative gene for AADC deficiency.
- name: TH biallelic pathogenic variants
  gene_term:
    preferred_term: TH
    term:
      id: hgnc:11782
      label: TH
  association: Causative biallelic pathogenic variants
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: Tyrosine hydroxylase deficiency
  evidence:
  - reference: DOI:10.1186/s12920-023-01510-1
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tyrosine hydroxylase deficiency (THD) is a rare movement disorder with
      broad phenotypic expression caused by bi-allelic mutations in the TH gene,
      which encode for tyrosine hydroxylase (TH) protein.
    explanation: Supports biallelic TH variants in TH deficiency.
- name: GCH1 pathogenic variants
  gene_term:
    preferred_term: GCH1
    term:
      id: hgnc:4193
      label: GCH1
  association: Causative biallelic/recessive variants affecting GTP cyclohydrolase I and BH4 synthesis
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: Autosomal recessive GTP cyclohydrolase I deficiency
  evidence:
  - reference: DOI:10.1002/mdc3.14157
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The GCH1 gene encodes the enzyme guanosine triphosphate cyclohydrolase I
      (GTPCH), which catalyzes the rate‐limiting step in the biosynthesis of
      tetrahydrobiopterin (BH4), a critical cofactor in the production of
      monoamine neurotransmitters.
    explanation: >-
      Supports GCH1 as the BH4 biosynthesis gene underlying GTP cyclohydrolase I
      deficiency.
- name: PTS pathogenic variants
  gene_term:
    preferred_term: PTS
    term:
      id: hgnc:9689
      label: PTS
  association: Causative variants affecting 6-pyruvoyltetrahydropterin synthase
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  evidence:
  - reference: DOI:10.1002/mgg3.2294
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We successfully identified six mutant alleles in BH4‐deficiency‐associated
      genes, including three novel mutations: one in QDPR, one in PTS, and one
      in the PCBD1 gene, thus giving a definite diagnosis to these patients.
    explanation: Supports PTS mutant alleles in human BH4 deficiency.
- name: QDPR pathogenic variants
  gene_term:
    preferred_term: QDPR
    term:
      id: hgnc:9752
      label: QDPR
  association: Causative variants affecting dihydropteridine reductase
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  evidence:
  - reference: DOI:10.1002/mgg3.2294
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We successfully identified six mutant alleles in BH4‐deficiency‐associated
      genes, including three novel mutations: one in QDPR, one in PTS, and one
      in the PCBD1 gene, thus giving a definite diagnosis to these patients.
    explanation: Supports QDPR mutant alleles in human BH4 deficiency.
- name: SPR pathogenic variants
  gene_term:
    preferred_term: SPR
    term:
      id: hgnc:11257
      label: SPR
  association: Causative variants affecting sepiapterin reductase
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: Sepiapterin reductase deficiency
  evidence:
  - reference: DOI:10.1002/mgg3.2294
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The latter is produced by mutations in genes involved in the
      tetrahydrobiopterin (BH4) biosynthesis pathway and DNAJC12 pathogenetic
      variants. The BH4 metabolism, including de novo biosynthesis involved
      genes (i.e., guanosine 5′‐triphosphate cyclohydrolase I (GTPCH/GCH1),
      sepiapterin reductase (SR/SPR), 6‐pyruvoyl‐tetrahydropterin synthase
      (PTPS/PTS)), and two genes that play roles in cofactor regeneration
      pathway (i.e., dihydropteridine reductase (DHPR/QDPR) and
      pterin‐4α‐carbinolamine dehydratase (PCD/PCBD1)).
    explanation: >-
      Supports SPR as a BH4 biosynthesis gene whose mutation can produce the
      non-PAH hyperphenylalaninemia/BH4-deficiency group.
- name: PCBD1 pathogenic variants
  gene_term:
    preferred_term: PCBD1
    term:
      id: hgnc:8646
      label: PCBD1
  association: Causative variants affecting pterin-4 alpha-carbinolamine dehydratase
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  evidence:
  - reference: DOI:10.1002/mgg3.2294
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We successfully identified six mutant alleles in BH4‐deficiency‐associated
      genes, including three novel mutations: one in QDPR, one in PTS, and one
      in the PCBD1 gene, thus giving a definite diagnosis to these patients.
    explanation: Supports PCBD1 mutant alleles in human BH4 deficiency.
- name: DNAJC12 pathogenic variants
  gene_term:
    preferred_term: DNAJC12
    term:
      id: hgnc:28908
      label: DNAJC12
  association: Pathogenic variants affecting monoamine synthesis co-chaperone function
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  subtype: DNAJC12-related monoamine synthesis disorder
  evidence:
  - reference: DOI:10.1002/mds.29677
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recent studies show that pathogenic variants in
                    DNAJC12
                    , a co‐chaperone for monoamine synthesis, may cause mild
      hyperphenylalaninemia with infantile dystonia, young‐onset parkinsonism,
      developmental delay and cognitive deficits.
    explanation: Supports DNAJC12 pathogenic variants as disease-causing.
diagnosis:
- name: Molecular genetic testing
  presence: Positive
  description: >-
    Molecular confirmation can identify DDC, TH, GCH1, PTS, QDPR, SPR, PCBD1,
    or DNAJC12 variants depending on the suspected subtype.
  evidence:
  - reference: DOI:10.3390/genes15010134
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Molecular investigation of the DDC gene was carried out with the aim of
      identifying affected patients and/or carriers.
    explanation: Supports DDC molecular testing in suspected AADC deficiency.
  - reference: DOI:10.1002/mgg3.2294
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We utilized the Sanger sequencing technique in this study to investigate
      14 Iranian patients with non‐PAH deficiency.
    explanation: Supports molecular testing in BH4/non-PAH deficiency.
- name: Homovanillic acid assessment
  presence: DECREASED
  description: >-
    Homovanillic acid is used as a pharmacodynamic biomarker in AADC gene
    therapy trials and can indicate dopamine pathway restoration or deficiency.
  evidence:
  - reference: clinicaltrials:NCT04903288
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The primary objectives of the trial phase are to assess the
      pharmacodynamics (PD) of eladocagene exuparvovec treatment by evaluation
      of homovanillic acid (HVA) levels and to assess the safety of the
      SmartFlow® magnetic resonance (MR) Compatible Ventricular Cannula for
      administering eladocagene exuparvovec to pediatric participants with
      aromatic L-amino acid decarboxylase (AADC) deficiency.
    explanation: Supports HVA as a monitored biomarker in AADC deficiency gene therapy.
- name: AADC deficiency CSF neurotransmitter profile
  presence: Abnormal
  description: >-
    AADC deficiency has a characteristic cerebrospinal fluid neurotransmitter
    pattern: low HVA, low 5-HIAA, low MHPG, elevated 3-OMD, L-DOPA, and 5-HTP,
    with normal pterins.
  evidence:
  - reference: PMID:19172410
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In CSF all patients revealed the pattern typical of AADC with decreased
      concentrations of homovanillic and 5-hydroxyindoleacetic acid and elevated
      concentration of 3-ortho-methyldopa.
    explanation: Supports low CSF HVA and 5-HIAA with elevated 3-OMD in AADC deficiency patients.
  - reference: PMID:1357595
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pterin and phenylalanine metabolism were normal.
    explanation: Supports normal pterin metabolism in AADC deficiency.
  - reference: PMID:1357595
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Concentrations of L-dopa, 3-methoxytyrosine, and 5-hydroxytryptophan were
      elevated in CSF, plasma, and urine.
    explanation: Supports elevated L-DOPA, 3-OMD/3-methoxytyrosine, and 5-HTP in the AADC biochemical profile.
- name: Dried blood spot 3-O-methyldopa newborn screening
  presence: INCREASED
  description: >-
    Elevated 3-O-methyldopa in dried blood spots can be used for AADC deficiency
    newborn screening and referral for confirmatory testing.
  evidence:
  - reference: PMID:37635029
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We demonstrated that an elevated concentration of L-dopa metabolite
      3-O-methyldopa (3-OMD) in dried blood spots could be integrated into a
      newborn screening program to detect AADC deficiency.
    explanation: Supports elevated DBS 3-OMD as a newborn-screening biomarker for AADC deficiency.
treatments:
- name: Carbidopa-levodopa
  description: >-
    Carbidopa-levodopa can improve dopamine-responsive manifestations in TH
    deficiency and related dopa-responsive dystonia phenotypes.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: levodopa
      term:
        id: CHEBI:15765
        label: L-dopa
  target_phenotypes:
  - preferred_term: Movement disorder
    term:
      id: HP:0100022
      label: Abnormality of movement
  target_mechanisms:
  - target: TH Enzymatic Deficiency
    treatment_effect: BYPASSES
  evidence:
  - reference: DOI:10.1186/s12920-023-01510-1
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Some patients with THD have improvement in dystonia with
      carbidopa–levodopa, a synthetic form of dopamine typically used in
      Parkinson’s disease, and are considered to have dopa-responsive THD.
    explanation: Supports carbidopa-levodopa for dopa-responsive TH deficiency.
  - reference: DOI:10.1186/s12920-023-01510-1
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The child was treated with carbidopa–levodopa with an excellent response,
      resulting in improved balance, fewer falls, and improved ability to jump,
      run and climb stairs.
    explanation: Case report supports clinical improvement with carbidopa-levodopa.
- name: AADC gene therapy
  description: >-
    AAV2-based gene supplementation with eladocagene exuparvovec or related
    hAADC vectors is a disease-directed therapy for AADC deficiency.
  treatment_term:
    preferred_term: gene therapy
    term:
      id: MAXO:0001001
      label: gene therapy
  target_mechanisms:
  - target: AADC Enzymatic Deficiency
    treatment_effect: RESTORES
  evidence:
  - reference: DOI:10.1002/jimd.12649
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Recently, the putaminally‐delivered construct, Eladocagene exuparvovec
      has been approved by the European Medicines Agency and by the British
      Medicines and Healthcare products Regulatory Agency.
    explanation: Supports eladocagene exuparvovec as an approved gene therapy for AADC deficiency.
  - reference: DOI:10.1002/jimd.12697
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Along with the recent European Medicines Agency (EMA) and Medicines and
      Healthcare Products Regulatory Agency (MHRA) approval of an AAV2 gene
      supplementation therapy for AADC deficiency, promising efficacy and safety
      profiles can be achieved in this group of diseases.
    explanation: Supports AAV2 gene supplementation therapy for AADC deficiency.
- name: Sapropterin/BH4 supplementation
  description: >-
    Sapropterin, a synthetic tetrahydrobiopterin analog, can be used to reduce
    blood phenylalanine in BH4-responsive hyperphenylalaninemia; for this
    umbrella entry it targets hyperphenylalaninemia caused by BH4-pathway
    defects.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: sapropterin
      term:
        id: CHEBI:59560
        label: sapropterin
  target_phenotypes:
  - preferred_term: Hyperphenylalaninemia
    term:
      id: HP:0004923
      label: Hyperphenylalaninemia
  target_mechanisms:
  - target: BH4 Cofactor Deficiency
    treatment_effect: RESTORES
  evidence:
  - reference: DOI:10.1002/mgg3.2294
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The latter is produced by mutations in genes involved in the
      tetrahydrobiopterin (BH4) biosynthesis pathway and DNAJC12 pathogenetic
      variants.
    explanation: Supports BH4-pathway defects as causes of non-PAH hyperphenylalaninemia in this disorder group.
  - reference: PMID:6119011
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Under BH4 therapy (16 mg daily), the dopamine values increased about
      twice, serotonin threefold and the phenylalanine blood concentration
      normalized to 1-1.5 mg/dl.
    explanation: >-
      Directly supports BH4 cofactor replacement in dihydrobiopterin synthetase
      deficiency, with improved monoamine metabolites and normalized
      phenylalanine.
- name: AADC symptomatic pharmacotherapy
  description: >-
    Conventional symptomatic regimens for AADC deficiency may include vitamin
    B6, dopamine agonists, and monoamine oxidase inhibitors, although responses
    are variable and often incomplete.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: pyridoxine
      term:
        id: CHEBI:16709
        label: pyridoxine
  target_phenotypes:
  - preferred_term: Movement disorder
    term:
      id: HP:0100022
      label: Abnormality of movement
  target_mechanisms:
  - target: AADC Enzymatic Deficiency
    treatment_effect: MODULATES
  evidence:
  - reference: PMID:19172410
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Drug regimes consisted of vitamin B6, dopamine agonists, MAO inhibitors
      and anticholinergics in different combinations.
    explanation: Supports vitamin B6, dopamine agonists, and MAO inhibitors as symptomatic pharmacotherapies used in AADC deficiency.
  - reference: PMID:19172410
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      No patient achieved a complete recovery from neurological symptoms, but
      partial improvement of mobility and mood could be achieved in some.
    explanation: Captures the limited and variable response to conventional symptomatic pharmacotherapy.
- name: Post-gene-therapy rehabilitation
  description: >-
    Rehabilitation after AADC gene therapy is recommended to help patients
    translate new motor capacity into functional gains.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
  target_phenotypes:
  - preferred_term: Motor delay
    term:
      id: HP:0001270
      label: Motor delay
  evidence:
  - reference: DOI:10.1186/s13023-024-03019-x
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      The approval of eladocagene exuparvovec, a gene therapy for AADC
      deficiency with demonstrated efficacy for motor improvements, now expands
      the range of motor outcomes possible for patients with this disorder.
    explanation: Supports rehabilitation needs after motor improvement from gene therapy.
  - reference: DOI:10.1186/s13023-024-03019-x
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Therefore, we highlight specific rehabilitative needs of patients
      following gene therapy and propose a set of recommendations for the
      post-treatment period based on collective experiences of therapists,
      physicians, and caregivers treating and caring for patients with AADC
      deficiency who have been treated with gene therapy.
    explanation: Supports post-treatment rehabilitation recommendations.
clinical_trials:
- name: NCT01395641
  phase: PHASE_I
  status: COMPLETED
  description: Phase I/II AAV2-hAADC trial for AADC deficiency.
  evidence:
  - reference: clinicaltrials:NCT01395641
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This Phase I/II trial is to prove the efficacy and safety of AAV2-hAADC
      to treat patients with AADC deficiency.
    explanation: Supports this trial as AADC gene therapy research.
- name: NCT04903288
  phase: PHASE_II
  status: COMPLETED
  description: Eladocagene exuparvovec trial using the SmartFlow MR-compatible cannula.
  evidence:
  - reference: clinicaltrials:NCT04903288
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The long-term extension phase is designed to capture long-term safety and
      efficacy data from participants treated with eladocagene exuparvovec.
    explanation: Supports long-term safety and efficacy follow-up for eladocagene exuparvovec.
- name: NCT05765981
  phase: PHASE_I
  status: RECRUITING
  description: Early-phase VGN-R09b AAV9-hAADC intra-striatum trial for AADC deficiency.
  evidence:
  - reference: clinicaltrials:NCT05765981
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      This early Phase trial is to prove the safety and efficacy of VGN-R09b to
      treat patients with AADC deficiency.
    explanation: Supports VGN-R09b as an AADC deficiency gene therapy trial.
- name: NCT02852213
  phase: PHASE_I
  status: RECRUITING
  description: AAV2-hAADC trial delivering vector to midbrain targets in pediatric AADC deficiency.
  evidence:
  - reference: clinicaltrials:NCT02852213
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The overall objective of this study is to determine the safety and
      efficacy of AAV2-hAADC delivered to the substantia nigra pars compacta
      (SNc) and ventral tegmental area (VTA) in children with aromatic L-amino
      acid decarboxylase (AADC) deficiency.
    explanation: Supports AAV2-hAADC midbrain delivery as an AADC deficiency trial.
datasets:

📚

References & Deep Research

Deep Research

1

Falcon ▸

1. Disease Information

Edison Scientific Literature 36 citations 2026-05-08T09:43:41.941074

1. Disease Information

1.1 Concise overview

Inherited disorders within this umbrella cause dopamine and other catecholamine deficiencies (norepinephrine, epinephrine) in the CNS and/or periphery due to defects in: - Biosynthesis enzymes (e.g., TH, AADC), - Cofactor pathways (BH4), - Associated transport/catabolism pathways (group-level differential diagnosis), - Or enzyme stability (DNAJC12 co‑chaperone).

They are rare neurodevelopmental diseases with predominant neurologic manifestations such as movement disorders, autonomic dysfunction, and developmental delay. (hubschmann2021insightsintothe pages 1-2, chu2024genetherapyfor pages 1-2)

1.2 Synonyms / alternative names (examples)

Because this is an umbrella, synonyms vary by subdisorder; key included entities: - AADC deficiency / Aromatic L‑amino acid decarboxylase deficiency / DDC deficiency. (paola2024aromaticlaminoacid pages 2-3) - Tyrosine hydroxylase deficiency (THD); overlaps with dopa‑responsive dystonia spectrum. (reyes2023diagnosisofautism pages 1-2) - BH4 deficiency disorders (BH4 biosynthesis/recycling defects leading to monoamine neurotransmitter deficiency ± hyperphenylalaninemia). (nezhad2024genotypicvariantsof pages 1-2) - Autosomal recessive GTP cyclohydrolase I deficiency (arGTPCH; recessive GCH1). (novelli2024autosomalrecessiveguanosine pages 1-2)

1.3 Evidence provenance

Evidence here is derived from: - Aggregated resources/registries (iNTD registry of 275 patients). (hubschmann2021insightsintothe pages 1-2) - Peer‑reviewed cohort/screening studies (e.g., Sicilian carrier screening for DDC). (paola2024aromaticlaminoacid pages 1-2) - Case reports (TH deficiency). (reyes2023diagnosisofautism pages 1-2) - Clinical trial registries and implementation reports for gene therapy. (NCT01395641 chunk 1, NCT04903288 chunk 1, mai2025framelessintraputaminaldelivery pages 1-2)

2. Etiology

2.1 Disease causal factors (primary)

Genetic: Pathogenic variants in genes encoding enzymes/cofactors required for catecholamine synthesis. - TH encodes tyrosine hydroxylase, which converts L‑tyrosine → L‑DOPA (rate-limiting step). (reyes2023diagnosisofautism pages 1-2) - DDC encodes AADC, which converts L‑DOPA → dopamine and 5‑HTP → serotonin, causing combined monoamine deficiency when impaired. (paola2024aromaticlaminoacid pages 1-2) - BH4-pathway genes (GCH1, PTS, QDPR, SPR, PCBD1) cause monoamine deficiency by limiting the BH4 cofactor required by TH and tryptophan hydroxylase, and can also cause hyperphenylalaninemia due to PAH impairment. (nezhad2024genotypicvariantsof pages 1-2) - DNAJC12 encodes a co‑chaperone for aromatic amino acid hydroxylases and interacts with TH/TPH/GCH1; biallelic variants cause a combined phenotype including monoamine deficiency. (deng2025centralbiogenicamine pages 1-2, deng2024dnajc12inmonoamine pages 1-5)

2.2 Risk factors

For inherited disorders, major risk factors are: - Family history and parental carrier status for autosomal recessive forms. (nezhad2024genotypicvariantsof pages 1-2) - Consanguinity increases incidence of BH4 deficiency in high-consanguinity regions, as emphasized in the Iranian BH4 gene-variant cohort. (nezhad2024genotypicvariantsof pages 1-2)

2.3 Protective factors

No robust protective environmental/genetic factors were identified in the retrieved evidence for the umbrella category.

2.4 Gene–environment interactions

Not established in the retrieved corpus for these rare Mendelian conditions.

3. Phenotypes (clinical features)

3.1 Cross-cutting phenotype patterns

The iNTD registry describes inherited biogenic amine disorders as rare neurodevelopmental diseases with movement disorders and global developmental delay, often presenting with nonspecific early symptoms and diagnostic delay. (hubschmann2021insightsintothe pages 1-2) Typical monoamine-related phenotypes include neonatal hypotonia, dystonia, parkinsonism, oculogyric crises, autonomic dysfunction and developmental delay. (chu2024genetherapyfor pages 1-2)

3.2 AADC (DDC) deficiency phenotypes and onset

AADC deficiency usually presents within the first months of life with: - Hypotonia, oculogyric crises, dystonia/hypokinesia, developmental delay, autonomic dysfunction and GI symptoms. (paola2024aromaticlaminoacid pages 1-2) Sentieri’s newborn-screening–oriented summary reports early onset and marked diagnostic delay: mean onset ~2.7 months and mean diagnosis ~3.5 years (secondary source within retrieved corpus). (sentieri2023analisideilivelli pages 21-25)

Quality of life impact: severe impairment of motor milestones and complications such as feeding difficulties, reflux/aspiration, contractures, scoliosis/hip dysplasia are highlighted in the rehabilitation position statement. (lee2024apositionstatement pages 1-2)

3.3 TH deficiency phenotypes and onset

TH deficiency is a rare autosomal recessive movement disorder caused by biallelic TH variants. It is part of the dopa‑responsive dystonia spectrum with phenotypes ranging from: 1) TH-deficient dopa-responsive dystonia, 2) TH-deficient infantile parkinsonism with motor delay, 3) TH-deficient progressive infantile encephalopathy. (reyes2023diagnosisofautism pages 1-2) The 2023 case report describes hypotonia and motor/speech delay in a ~3-year-old child, with excellent response to carbidopa–levodopa. (reyes2023diagnosisofautism pages 1-2)

3.4 BH4 deficiency disorders (group) phenotypes

BH4 deficiencies can produce systemic hyperphenylalaninemia plus CNS monoamine deficiency leading to neurological consequences (developmental problems, seizures, intellectual disability, movement disorders). (nezhad2024genotypicvariantsof pages 1-2)

3.5 Suggested HPO terms (non-exhaustive)

(Provided as ontology suggestions; not directly extracted from source texts.) - Hypotonia (HP:0001252) - Developmental delay (HP:0001263) - Dystonia (HP:0001332) - Parkinsonism (HP:0001300) - Oculogyric crisis (HP:0002173) - Autonomic dysfunction (HP:0002270) - Feeding difficulties (HP:0011968) - Seizures (HP:0001250)

4. Genetic/Molecular Information

4.1 Causal genes (core set supported in retrieved evidence)

DDC (AADC deficiency). (paola2024aromaticlaminoacid pages 1-2, OpenTargets Search: aromatic L-amino acid decarboxylase deficiency,tyrosine hydroxylase deficiency,dopamine beta-hydroxylase deficiency)
TH (TH deficiency). (reyes2023diagnosisofautism pages 1-2)
GCH1 (autosomal recessive GTPCH deficiency; BH4). (novelli2024autosomalrecessiveguanosine pages 1-2)
PTS, QDPR, SPR, PCBD1 (BH4 biosynthesis/recycling disorders). (nezhad2024genotypicvariantsof pages 1-2)
DNAJC12 (co‑chaperone disorder impacting TH/TPH/GCH1). (deng2024dnajc12inmonoamine pages 1-5, deng2025centralbiogenicamine pages 1-2)

4.2 Pathway and biochemical roles (key concepts)

The gene-therapy review of neurotransmitter-related disorders summarizes monoamine biosynthesis: dopamine is made from L‑tyrosine by TH (BH4-dependent) then by AADC (PLP-dependent), and synaptic DA handling involves DAT/VMAT2. (chu2024genetherapyfor pages 1-2)

The extracted pathway figure from Roubertie et al. provides a visual schematic of monoamine synthesis and is appropriate to cite for pathway representation. (roubertie2024genetherapyfor media e0e2cf3d)

4.3 DNAJC12 mechanistic insight (model organism + human phenotype)

The 2025 NPJ Parkinson’s Disease paper provides mechanistic support that DNAJC12 interacts with TH/TPH/GCH1 and that loss destabilizes a DNAJC12–TH–GCH1 complex; Dnajc12 knockout mice show reduced striatal dopamine and serotonin and exploratory behavioral deficits. (deng2025centralbiogenicamine pages 1-2, deng2025centralbiogenicamine pages 2-4) The 2024 Movement Disorders review summarizes that DNAJC12 pathogenic variants can cause mild hyperphenylalaninemia with infantile dystonia, young‑onset parkinsonism, developmental delay, and cognitive deficits, and notes incorporation of DNAJC12 into newborn screening programs (Spain). (deng2024dnajc12inmonoamine pages 1-5)

4.4 Suggested GO and CL terms (non-exhaustive)

(Provided as ontology suggestions.) - Dopamine biosynthetic process (GO:0042417) - Catecholamine biosynthetic process (GO:0042423) - Tetrahydrobiopterin biosynthetic process (GO:0006729) - Tyrosine hydroxylase activity (GO:0004507) - Aromatic L-amino acid decarboxylase activity (GO:0004059) - Dopaminergic neuron (CL:0000700) - Noradrenergic neuron (CL:0000820) - Serotonergic neuron (CL:0000850)

5. Environmental Information

No specific environmental exposures causing the inherited enzyme/cofactor defects were identified in the retrieved corpus; however, environmental context is relevant for screening false positives in AADC newborn screening (e.g., maternal dopaminergic medications may elevate DBS 3‑OMD). (sentieri2023analisideilivelli pages 21-25)

6. Mechanism / Pathophysiology

6.1 Causal chain (AADC deficiency as exemplar)

DDC loss-of-function → reduced AADC activity → reduced dopamine + serotonin synthesis → downstream reduced norepinephrine/epinephrine → motor dysfunction + autonomic dysfunction + developmental delay; with accumulation of upstream metabolites (notably 3‑O‑methyldopa/3‑OMD). (paola2024aromaticlaminoacid pages 1-2, sentieri2023analisideilivelli pages 21-25)

6.2 Key biochemical abnormalities and biomarkers

AADC deficiency CSF signature: low 5‑HIAA, HVA, and MHPG; elevated 3‑OMD, L‑DOPA and 5‑OH tryptophan; normal pterins. (paola2024aromaticlaminoacid pages 1-2)
AADC newborn screening biomarker: markedly elevated DBS 3‑OMD; Sentieri reports mean patient DBS 3‑OMD ~1,113 ng/mL (range 530–2,430 ng/mL) and gives population newborn levels far lower (study-dependent); the same source notes large-cohort screening and incidence inference in Taiwan. (sentieri2023analisideilivelli pages 21-25)
TH deficiency: TH catalyzes the rate‑limiting step in catecholamine synthesis; TH deficiency phenotypes reflect dopamine and downstream catecholamine deficiency and can respond to levodopa. (reyes2023diagnosisofautism pages 1-2)

6.3 Gene therapy mechanism (AADC)

AADC gene therapy uses a recombinant AAV vector carrying human DDC (hAADC) delivered stereotactically to the putamen to restore AADC activity locally in basal ganglia circuits. (roubertie2024genetherapyfor pages 4-4, NCT04903288 chunk 1) The extracted schematic figure can be cited for vector/delivery conceptualization. (roubertie2024genetherapyfor media d99c2658)

7. Anatomical Structures Affected

7.1 Primary systems

Predominantly central nervous system, with motor and neurodevelopmental phenotypes, plus systemic autonomic manifestations. (hubschmann2021insightsintothe pages 1-2, chu2024genetherapyfor pages 1-2)

7.2 Key neuroanatomical targets in therapy/biomarkers

Putamen is the principal intracerebral delivery site for approved AADC gene therapy and several clinical trials. (roubertie2024genetherapyfor pages 4-4, NCT04903288 chunk 1)

Suggested UBERON terms (non-exhaustive): - Putamen (UBERON:0001874) - Basal ganglion (UBERON:0002420) - Brain (UBERON:0000955)

8. Temporal Development

8.1 Onset

AADC deficiency: typically within the first months of life (mean onset ~2.7 months in one newborn-screening–oriented dataset). (sentieri2023analisideilivelli pages 21-25, paola2024aromaticlaminoacid pages 1-2)
TH deficiency: can present in infancy/childhood; spectrum includes infantile parkinsonism and encephalopathy, but milder DRD presentations occur. (reyes2023diagnosisofautism pages 1-2)

8.2 Progression/course

The iNTD registry indicates phenotypes range from mild hypotonia and late-onset movement disorders to early-onset lethal encephalopathies, and diagnostic delay has decreased in recent years. (hubschmann2021insightsintothe pages 1-2)

9. Inheritance and Population

9.1 Inheritance patterns

AADC (DDC) deficiency: autosomal recessive. (paola2024aromaticlaminoacid pages 1-2)
TH deficiency: autosomal recessive. (reyes2023diagnosisofautism pages 1-2)
BH4 biosynthesis/recycling disorders (PTS, QDPR, SPR, PCBD1): generally autosomal recessive. (nezhad2024genotypicvariantsof pages 1-2)
Autosomal recessive GCH1 deficiency: autosomal recessive. (novelli2024autosomalrecessiveguanosine pages 1-2)
DNAJC12 deficiency: autosomal recessive. (deng2024dnajc12inmonoamine pages 1-5)

9.2 Epidemiology highlights (recent evidence)

AADC deficiency: founder-effect incidence estimate in Taiwan ~1:32,000 births. (paola2024aromaticlaminoacid pages 1-2, sentieri2023analisideilivelli pages 21-25)
Sicilian carrier frequency: DDC carrier frequency 2.57% in a Sicilian cohort of 350 unrelated patients with neurological disorders (authors caution representativeness). (paola2024aromaticlaminoacid pages 1-2)
TH/DRD prevalence: estimated 0.5–1 per million for dopa-responsive dystonias (noting underestimation). (reyes2023diagnosisofautism pages 1-2)
Hyperphenylalaninemia prevalence examples: reported wide variation (e.g., China 1/15,415; Japan 1/143,000; Turkey ~1:2,600; pooled ~38–43.3/100,000). (nezhad2024genotypicvariantsof pages 1-2)

10. Diagnostics

10.1 Core diagnostic approach (umbrella)

Biochemical testing in blood/urine/CSF remains central to diagnosing neurotransmitter disorders and interpreting genetic variants, while MRI/EEG are often non-specific. (kulhanek2026studyofdiagnostica pages 46-49)
Increasingly, exome/genome sequencing can accelerate diagnosis and may precede CSF studies in some settings. (chu2024genetherapyfor pages 1-2)

10.2 AADC deficiency biomarkers (recommended)

CSF: low HVA/5‑HIAA/MHPG and elevated 3‑OMD/L‑DOPA/5‑HTP with normal pterins. (paola2024aromaticlaminoacid pages 1-2)
DBS: elevated 3‑OMD enables newborn screening and earlier identification. (sentieri2023analisideilivelli pages 21-25)

10.3 TH deficiency diagnostics

TH deficiency diagnosis is suggested by biochemical neurotransmitter patterns (e.g., low CSF HVA) and confirmed by biallelic TH variants; clinical response to levodopa can be prominent. (reyes2023diagnosisofautism pages 1-2)

10.4 Differential diagnosis (high level)

Inherited biogenic amine disorders include biosynthesis, catabolism, transport, BH4, and co-chaperone defects; thus differential diagnosis spans multiple gene classes beyond “catecholamine synthesis” alone. (hubschmann2021insightsintothe pages 1-2)

11. Outcome / Prognosis

11.1 Prognosis without disease-modifying therapy

The iNTD registry notes some disorders can manifest as early-onset severe encephalopathies, while others are milder; misdiagnosis and delayed diagnosis are common. (hubschmann2021insightsintothe pages 1-2)

11.2 Gene therapy outcomes in AADC deficiency

The rehabilitation position statement summarizes that after eladocagene exuparvovec, motor improvements can be observed as early as 3 months; PDMS‑2 and AIMS gains can persist over years, with some patients walking independently within ~3 years, and common events include fever and transient dyskinesia. (lee2024apositionstatement pages 1-2)

12. Treatment

12.1 Pharmacotherapy (supportive/symptomatic and pathway-based)

A diagnostic/treatment overview (Kulhánek) describes general neurotransmitter-disorder strategies: - Precursor replacement (L‑DOPA with peripheral decarboxylase inhibitor; and serotonin pathway precursors), - Dopamine agonists (e.g., pramipexole), - MAO‑B inhibitors (e.g., selegiline), - BH4 analog supplementation (sapropterin) and Phe control in HPA-related disorders, - Vitamin B6 supplementation and multidisciplinary supportive care. (kulhanek2026studyofdiagnostica pages 46-49)

12.2 Disease-modifying therapy: AADC gene therapy (eladocagene exuparvovec)

Regulatory milestone: EU approval July 2022 for severe AADC deficiency (summarized in first-approval review and in disease-specific papers). (paola2024aromaticlaminoacid pages 2-3)
Expert implementation guidance: iNTD Delphi recommendations emphasize a quality-assured framework, specialized multidisciplinary centers, and structured long-term follow-up/registry documentation due to limited comparative long-term data. (roubertie2024genetherapyfor pages 3-3)
Post-treatment rehabilitation expert opinion: a 2024 position statement provides pragmatic rehab recommendations to maximize functional gains after gene therapy. (lee2024apositionstatement pages 1-2)

12.3 Clinical trials (selected; gene therapy)

Key AADC gene therapy trials and endpoints: - NCT01395641 (AAV2-hAADC, bilateral putamen; Phase I/II; completed; n=10). Primary endpoints include increase in CSF HVA or 5‑HIAA and >10-point PDMS‑II improvement at 12 months. Start 2014-10-22; completion 2022-03-07. (NCT01395641 chunk 1) - NCT04903288 (eladocagene exuparvovec delivered with SmartFlow MR-compatible cannula; Phase 2; includes CSF HVA primary endpoint at Week 8; includes PET, PDMS‑2, Bayley‑III, EQ‑5D‑Y). Start 2021-05-12; results posted 2025-01-01. (NCT04903288 chunk 1) - NCT05765981 (VGN‑R09b AAV9-hAADC; Early Phase 1; recruiting; bilateral putamen injection; primary safety and PDMS-II milestone ratio at Week 52). Start 2023-01-30. (NCT05765981 chunk 1) - NCT02852213 (AAV2-hAADC delivered to midbrain targets SNc/VTA; Phase 1; recruiting; includes CSF metabolites and motor scales). Start 2016-07-01. (NCT02852213 chunk 1)

12.4 Suggested MAXO terms (examples)

(Provided as ontology suggestions.) - Levodopa therapy (MAXO:0000139) - Dopamine agonist therapy (MAXO:0000153) - Monoamine oxidase inhibitor therapy (MAXO:0000191) - Gene therapy (MAXO:0000010) - Newborn screening (MAXO:0000796) - Physical therapy (MAXO:0000012) - Occupational therapy (MAXO:0000013)

13. Prevention

13.1 Secondary prevention: newborn screening

AADC deficiency can be piloted for newborn screening via DBS 3‑OMD using LC‑MS/MS workflows; Sentieri describes feasibility, stability of the marker, and large-cohort screening with incidence inference. (sentieri2023analisideilivelli pages 21-25)
Newborn screening programs detect BH4 deficiencies associated with hyperphenylalaninemia (HPA). (kulhanek2026studyofdiagnostica pages 46-49)

14. Other Species / Natural Disease

No naturally occurring non-human disease analogs were identified in the retrieved evidence for catecholamine synthesis disorders specifically.

15. Model Organisms

A mechanistically informative model organism for the broader umbrella is the Dnajc12 knock-out mouse, which shows reduced striatal dopamine/serotonin and exploratory behavioral deficits, providing an experimental platform for therapeutic development in biogenic amine disorders. (deng2025centralbiogenicamine pages 1-2, deng2025centralbiogenicamine pages 2-4)

Key concepts and definitions (consolidated)

Catecholamine synthesis relies on TH (BH4-dependent) and AADC (PLP-dependent) as core enzymatic steps; defects produce dopamine deficiency and downstream norepinephrine/epinephrine deficiency. (chu2024genetherapyfor pages 1-2, reyes2023diagnosisofautism pages 1-2)
BH4 (tetrahydrobiopterin) is a critical cofactor required for TH/TPH/PAH; BH4 disorders can manifest as HPA plus CNS monoamine deficiency. (nezhad2024genotypicvariantsof pages 1-2)
AADC deficiency is now in a “new therapeutic era” because intracerebral AAV gene supplementation has been approved by EMA/MHRA, with expert consensus emphasizing specialized delivery and systematic follow-up. (roubertie2024genetherapyfor pages 3-3, chu2024genetherapyfor pages 1-2)

Recent developments and real-world implementation highlights (2023–2024 prioritized)

2024 gene therapy implementation guidance: Delphi-based recommendations for safe application and structured follow-up/registry documentation for AADC gene therapy. (Roubertie et al., 2024-07-??; https://doi.org/10.1002/jimd.12649) (roubertie2024genetherapyfor pages 3-3)
2024 rehabilitation expert consensus: post–gene-therapy rehabilitation recommendations to maximize functional gains after AADC gene therapy. (Lee et al., 2024-01; https://doi.org/10.1186/s13023-024-03019-x) (lee2024apositionstatement pages 1-2)
2024 population genetics/screening evidence: Sicilian DDC carrier frequency 2.57% in neurological cohort; reinforces need for awareness/screening strategies. (Paola et al., 2024-01; https://doi.org/10.3390/genes15010134) (paola2024aromaticlaminoacid pages 1-2)
2023–2024 newborn screening biomarker: DBS 3‑OMD as robust marker for AADC deficiency, with large-cohort screening and Taiwan incidence estimate ~1:32,000. (sentieri2023analisideilivelli pages 21-25)

Statistics and data (recent studies)

AADC deficiency: Taiwan incidence estimate ~1:32,000 births. (sentieri2023analisideilivelli pages 21-25, paola2024aromaticlaminoacid pages 1-2)
AADC deficiency: patient DBS 3‑OMD levels reported mean ~1,113 ng/mL (range 530–2,430 ng/mL) in one summary. (sentieri2023analisideilivelli pages 21-25)
TH/DRD spectrum prevalence estimate: 0.5–1 per million (noting likely underestimation). (reyes2023diagnosisofautism pages 1-2)
Sicilian cohort: DDC carrier frequency 2.57% among 350 unrelated neurological patients (authors discuss extrapolation cautiously). (paola2024aromaticlaminoacid pages 1-2)
Autosomal recessive GCH1 deficiency: pooled series 45 patients and three phenotypic strata. (novelli2024autosomalrecessiveguanosine pages 1-2)

Evidence-backed abstract quotes (selected)

AADC (Genes 2024) abstract: “Aromatic L-amino acid decarboxylase deficiency (AADCd) is a rare autosomal recessive neurometabolic disorder caused by AADC deficiency, an enzyme encoded by the DDC gene.” and “Taiwan is the site of a potential founder variant (IVS6+4A>T) with a predicted incidence of 1/32,000 births…” (Paola et al., 2024-01; https://doi.org/10.3390/genes15010134) (paola2024aromaticlaminoacid pages 1-2)
AADC rehabilitation position statement (Orphanet 2024) abstract: “The approval of eladocagene exuparvovec, a gene therapy for AADC deficiency with demonstrated efficacy for motor improvements, now expands the range of motor outcomes possible for patients with this disorder.” (Lee et al., 2024-01; https://doi.org/10.1186/s13023-024-03019-x) (lee2024apositionstatement pages 1-2)
Gene therapy for neurotransmitter disorders (JIMD 2024) abstract: “Along with the recent European Medicines Agency (EMA) and Medicines and Healthcare Products Regulatory Agency (MHRA) approval of an AAV2 gene supplementation therapy for AADC deficiency, promising efficacy and safety profiles can be achieved in this group of diseases.” (Chu et al., 2024-01; https://doi.org/10.1002/jimd.12697) (chu2024genetherapyfor pages 1-2)
BH4 gene-variant cohort (MGGM 2024) abstract: “The subsequent systemic hyperphenylalaninemia and monoamine neurotransmitter deficiency lead to neurological consequences.” (Nezhad et al., 2024-10; https://doi.org/10.1002/mgg3.2294) (nezhad2024genotypicvariantsof pages 1-2)
DNAJC12 review (Movement Disorders 2024) abstract: “Recent studies show that pathogenic variants in DNAJC12… may cause mild hyperphenylalaninemia with infantile dystonia, young-onset parkinsonism, developmental delay and cognitive deficits.” (Deng et al., 2024-11; https://doi.org/10.1002/mds.29677) (deng2024dnajc12inmonoamine pages 1-5)
Dnajc12 KO mouse (npj Parkinson’s Disease 2025) abstract: “Bi-allelic autosomal recessive pathogenic variants in DNAJC12 lead to a constellation of neurological features, including young-onset Parkinson’s disease. DNAJC12 is a co-chaperone for enzymes involved in biogenic amines synthesis.” (Deng et al., 2025-05; https://doi.org/10.1038/s41531-025-00991-4) (deng2025centralbiogenicamine pages 2-4)

Visual evidence (pathway and vector schematic)

The monoamine/catecholamine synthesis pathway schematic and the AADC gene therapy vector/delivery schematic were extracted from Roubertie et al. 2024. (roubertie2024genetherapyfor media e0e2cf3d, roubertie2024genetherapyfor media d99c2658)

Structured gene/phenotype scaffold

Disorder (umbrella)	Causal gene(s)	Enzyme/cofactor role in pathway	Typical biochemical signature (CSF/DBS where available)	Key clinical features	Inheritance	Notable epidemiology stats	Key references (with URLs, dates)	Evidence context IDs
Aromatic L-amino acid decarboxylase (AADC) deficiency	DDC	AADC converts L-DOPA → dopamine and 5-HTP → serotonin; downstream deficiency also lowers norepinephrine/epinephrine	CSF: low HVA, low 5-HIAA, low MHPG; high 3-OMD, L-DOPA, 5-HTP; normal pterins. DBS/newborn screening: elevated 3-OMD	Infantile onset; hypotonia, oculogyric crises, dystonia/hypokinesia, developmental delay, autonomic dysfunction, feeding/GI symptoms, sleep/behavior problems; severe and mild/moderate phenotypes reported	Autosomal recessive	Taiwan founder variant associated with predicted incidence ~1/32,000 births; one 2024 review noted 261 reported patients globally and Sicilian neurological cohort carrier frequency 2.57%	Paola et al., Genes (2024-01), https://doi.org/10.3390/genes15010134 ; Roubertie et al., J Inherit Metab Dis (2024-07), https://doi.org/10.1002/jimd.12649 ; Lee et al., Orphanet J Rare Dis (2024-01), https://doi.org/10.1186/s13023-024-03019-x	(paola2024aromaticlaminoacid pages 2-3, lee2024apositionstatement pages 1-2, paola2024aromaticlaminoacid pages 1-2, roubertie2024genetherapyfor pages 4-4)
Tyrosine hydroxylase deficiency (THD)	TH	TH catalyzes tyrosine → L-DOPA, the rate-limiting step in catecholamine synthesis; requires BH4	Diagnosis suggested by low CSF HVA and confirmed by biallelic TH variants; 3-OMD may be low/reduced as surrogate of reduced TH activity in CSF workflows	Spectrum from dopa-responsive dystonia to infantile parkinsonism and progressive infantile encephalopathy; hypotonia, dystonia/parkinsonism, motor delay; some patients improve markedly with carbidopa/levodopa	Autosomal recessive	Reported prevalence for dopa-responsive dystonias/THD spectrum ~0.5–1 per million (likely underestimated)	Reyes et al., BMC Med Genomics (2023-04), https://doi.org/10.1186/s12920-023-01510-1 ; Bondarenko et al., J Inherit Metab Dis (2025-11), https://doi.org/10.1002/jimd.70106	(reyes2023diagnosisofautism pages 1-2)
Autosomal recessive GTP cyclohydrolase I deficiency (BH4 deficiency subtype)	GCH1	GTPCH catalyzes the first/rate-limiting step in BH4 biosynthesis; BH4 is required for TH and tryptophan hydroxylase, affecting dopamine, norepinephrine, epinephrine, serotonin synthesis	Gradient of BH4 biochemical defect by phenotype; hyperphenylalaninemia common in severe early-infantile forms and absent in later dystonia-parkinsonism/DRD groups; abnormal biogenic amines/pterins support diagnosis	Three described phenotypes: early-infantile encephalopathic, dystonia-parkinsonism with developmental stagnation/regression, and late-onset dopa-responsive dystonia; early treatment improves outcome	Autosomal recessive	UltraraRE; pooled series 45 patients in 2024 review. For comparison, dominant GCH1 deficiency prevalence estimated ~0.5–1.0/million	Novelli et al., Mov Disord Clin Pract (2024-07), https://doi.org/10.1002/mdc3.14157	(novelli2024autosomalrecessiveguanosine pages 1-2)
BH4 biosynthesis/recycling disorders (group umbrella)	PTS, QDPR, SPR, PCBD1 (also BH4-related GCH1)	BH4 synthesis/recycling enzymes maintain tetrahydrobiopterin, the essential cofactor for TH, tryptophan hydroxylase, and PAH; deficiency causes monoamine neurotransmitter deficiency ± hyperphenylalaninemia	Group features include abnormal pterins, HPA in many subtypes, and CSF monoamine abnormalities (low HVA/5-HIAA expected in BH4-related monoamine deficiency). Blood Phe alone does not distinguish PAH from BH4 disorders	Neurodevelopmental delay, intellectual disability, seizures, movement disorder, depletion of brain dopamine/serotonin/norepinephrine; some disorders detected by newborn screening because they present with HPA	Usually autosomal recessive	HPA prevalence examples reported in 2024 review: China 1/15,415, Japan 1/143,000, Turkey ~1:2,600, pooled estimates ~38–43.3/100,000; consanguinity increases BH4-deficiency incidence in some regions	Nezhad et al., Mol Genet Genomic Med (2024-10), https://doi.org/10.1002/mgg3.2294	(nezhad2024genotypicvariantsof pages 1-2)
6-pyruvoyl-tetrahydropterin synthase deficiency	PTS	PTPS is a core BH4 biosynthesis enzyme upstream of catecholamine/serotonin synthesis	Typically BH4-deficiency pattern with HPA, abnormal pterins, and monoamine deficiency on CSF neurotransmitter studies	Developmental delay, seizures, movement disorder, monoamine deficiency symptoms; mild forms may respond relatively well to treatment	Autosomal recessive	2024 variant review listed ~199 PTS variants in PNDdb	Nezhad et al., Mol Genet Genomic Med (2024-10), https://doi.org/10.1002/mgg3.2294	(nezhad2024genotypicvariantsof pages 1-2)
Dihydropteridine reductase deficiency	QDPR	DHPR regenerates BH4 from quinonoid dihydrobiopterin; failure impairs catecholamine/serotonin synthesis and PAH function	BH4-deficiency pattern with HPA, abnormal pterins, and CSF monoamine deficiency; folate disturbance may be clinically relevant in DHPR deficiency management literature	Developmental delay, seizures, movement disorder, monoamine deficiency; neurologic consequences reflect dopamine/serotonin/norepinephrine depletion	Autosomal recessive	2024 variant review listed ~141 QDPR variants in PNDdb	Nezhad et al., Mol Genet Genomic Med (2024-10), https://doi.org/10.1002/mgg3.2294	(nezhad2024genotypicvariantsof pages 1-2)
Sepiapterin reductase deficiency	SPR	SR catalyzes a late BH4 biosynthesis step; deficiency impairs dopamine/serotonin synthesis and may occur without marked HPA	Typically a BH4/monoamine deficiency phenotype; pterin/CSF neurotransmitter testing is important because blood phenylalanine alone may miss non-HPA BH4 disorders	Developmental delay, dystonia/parkinsonism, oculogyric crises, other neurotransmitter-deficiency manifestations	Autosomal recessive	2024 variant review listed ~104 SPR variants in PNDdb	Nezhad et al., Mol Genet Genomic Med (2024-10), https://doi.org/10.1002/mgg3.2294	(nezhad2024genotypicvariantsof pages 1-2)
Pterin-4α-carbinolamine dehydratase deficiency	PCBD1	PCD/PCBD1 functions in BH4 recycling	Usually identified in BH4-deficiency/HPA workup with abnormal pterin profile; molecular confirmation required because blood Phe is nonspecific	Can contribute to BH4-related HPA and monoamine deficiency spectrum; clinical severity variable	Autosomal recessive	2024 variant review listed ~32 PCBD1 variants in PNDdb	Nezhad et al., Mol Genet Genomic Med (2024-10), https://doi.org/10.1002/mgg3.2294	(nezhad2024genotypicvariantsof pages 1-2)
DNAJC12-related monoamine synthesis disorder	DNAJC12	DNAJC12 is a co-chaperone for enzymes involved in monoamine synthesis, including interaction with TH and GCH1; destabilization impairs dopamine/serotonin biosynthesis	May present with mild HPA plus central biogenic amine deficiency; mechanism supported by reduced striatal dopamine/serotonin in knockout models and impaired TH/GCH1 complex stability	Infantile dystonia, developmental delay, cognitive deficits, young-onset parkinsonism; emphasizes importance of early genetic diagnosis and intervention	Autosomal recessive	Included in newborn screening in some regions (e.g., Spain, per 2024 review); many adult patients may still be undiagnosed	Deng et al., Movement Disorders (2024-11), https://doi.org/10.1002/mds.29677 ; Deng et al., npj Parkinsons Dis (2025-05), https://doi.org/10.1038/s41531-025-00991-4	(nezhad2024genotypicvariantsof pages 1-2, novelli2024autosomalrecessiveguanosine pages 1-2)

Table: This table summarizes the principal inherited genetic causes grouped under disorders of catecholamine synthesis/biogenic amine disorders, emphasizing pathway role, diagnostic biochemical signatures, phenotypes, inheritance, and recent references. It is useful as a compact disease-knowledge-base scaffold linking umbrella categories to specific genes and biomarkers.

Key evidence gaps (explicit)

DBH (dopamine β-hydroxylase) deficiency and PNMT deficiency: not well covered by retrievable full-text evidence in this run; droxidopa is referenced in clinical trial search results broadly but not linked to primary DBH-deficiency cohorts in the retrieved evidence set.
Granular variant-level details (ClinVar classifications, gnomAD frequencies): not retrievable with the available tools in this run.
OMIM/Orphanet/ICD/MeSH cross-IDs: not retrievable with the available tools in this run.

References

(hubschmann2021insightsintothe pages 1-2): Oya Kuseyri Hübschmann, Gabriella Horvath, Elisenda Cortès-Saladelafont, Yılmaz Yıldız, Mario Mastrangelo, Roser Pons, Jennifer Friedman, Saadet Mercimek-Andrews, Suet-Na Wong, Toni S. Pearson, Dimitrios I. Zafeiriou, Jan Kulhánek, Manju A. Kurian, Eduardo López-Laso, Mari Oppebøen, Sebile Kılavuz, Tessa Wassenberg, Helly Goez, Sabine Scholl-Bürgi, Francesco Porta, Tomáš Honzík, René Santer, Alberto Burlina, H. Serap Sivri, Vincenzo Leuzzi, Georg F. Hoffmann, Kathrin Jeltsch, Daniel Hübschmann, Sven F. Garbade, Birgit Assmann, Cheuk-Wing Fung, Philipp Guder, Stacey Tay Kiat Hong, Daniela Karall, Mitsuhiro Kato, Ivana Kavecan, Jeanette Aimee Koht, Alice Kuster, Thomas Lücke, Filippo Manti, Pablo Mir, Chris Mühlhausen, Halise Neslihan Önenli Mungan, Natalia Alexandra Julia Palacios, Joaquín Alejandro Fernández Ramos, Dora Steel, Galina Stevanović, Jolanta Sykut-Cegielska, Marcel M. Verbeek, Angeles García-Cazorla, and Thomas Opladen. Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines. Nature Communications, Sep 2021. URL: https://doi.org/10.1038/s41467-021-25515-5, doi:10.1038/s41467-021-25515-5. This article has 49 citations and is from a highest quality peer-reviewed journal.
(OpenTargets Search: aromatic L-amino acid decarboxylase deficiency,tyrosine hydroxylase deficiency,dopamine beta-hydroxylase deficiency): Open Targets Query (aromatic L-amino acid decarboxylase deficiency,tyrosine hydroxylase deficiency,dopamine beta-hydroxylase deficiency, 6 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(chu2024genetherapyfor pages 1-2): Wing Sum Chu, Joanne Ng, Simon N. Waddington, and Manju A. Kurian. Gene therapy for neurotransmitter‐related disorders. Journal of Inherited Metabolic Disease, 47:176-191, Jan 2024. URL: https://doi.org/10.1002/jimd.12697, doi:10.1002/jimd.12697. This article has 13 citations and is from a peer-reviewed journal.
(paola2024aromaticlaminoacid pages 2-3): Sandro Santa Paola, Francesco Domenico Di Blasi, Eugenia Borgione, Mariangela Lo Giudice, Marika Giuliano, Rosa Pettinato, Vincenzo Di Stefano, Filippo Brighina, Antonino Lupica, and Carmela Scuderi. Aromatic l-amino acid decarboxylase deficiency: a genetic screening in sicilian patients with neurological disorders. Genes, 15:134, Jan 2024. URL: https://doi.org/10.3390/genes15010134, doi:10.3390/genes15010134. This article has 2 citations.
(reyes2023diagnosisofautism pages 1-2): Zoe Maria Dominique Reyes, Emma Lynch, Julia Henry, Lenika Marina De Simone, and Sarah A. Sobotka. Diagnosis of autism in a rare case of tyrosine hydroxylase deficiency: a case report. BMC Medical Genomics, Apr 2023. URL: https://doi.org/10.1186/s12920-023-01510-1, doi:10.1186/s12920-023-01510-1. This article has 4 citations and is from a peer-reviewed journal.
(nezhad2024genotypicvariantsof pages 1-2): Seyed Reza Kazemi Nezhad, Pegah Namdar Aligoodarzi, Golale Rostami, Gholamreza Shariati, Hamid Galehdari, Alihossein Saberi, Alireza Sedaghat, and Mohammad Hamid. Genotypic variants of the tetrahydrobiopterin (bh4) biosynthesis genes in patients with hyperphenylalaninemia from different regions of iran. Molecular Genetics & Genomic Medicine, Oct 2024. URL: https://doi.org/10.1002/mgg3.2294, doi:10.1002/mgg3.2294. This article has 5 citations and is from a peer-reviewed journal.
(novelli2024autosomalrecessiveguanosine pages 1-2): Maria Novelli, Manuela Tolve, Vicente Quiroz, Claudia Carducci, Rossella Bove, Giacomina Ricciardi, Kathryn Yang, Filippo Manti, Francesco Pisani, Darius Ebrahimi‐Fakhari, Serena Galosi, and Vincenzo Leuzzi. Autosomal recessive guanosine triphosphate cyclohydrolase i deficiency: redefining the phenotypic spectrum and outcomes. Movement Disorders Clinical Practice, 11:1072-1084, Jul 2024. URL: https://doi.org/10.1002/mdc3.14157, doi:10.1002/mdc3.14157. This article has 5 citations and is from a peer-reviewed journal.
(paola2024aromaticlaminoacid pages 1-2): Sandro Santa Paola, Francesco Domenico Di Blasi, Eugenia Borgione, Mariangela Lo Giudice, Marika Giuliano, Rosa Pettinato, Vincenzo Di Stefano, Filippo Brighina, Antonino Lupica, and Carmela Scuderi. Aromatic l-amino acid decarboxylase deficiency: a genetic screening in sicilian patients with neurological disorders. Genes, 15:134, Jan 2024. URL: https://doi.org/10.3390/genes15010134, doi:10.3390/genes15010134. This article has 2 citations.
(NCT01395641 chunk 1): A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC. National Taiwan University Hospital. 2014. ClinicalTrials.gov Identifier: NCT01395641
(NCT04903288 chunk 1): A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants. PTC Therapeutics. 2021. ClinicalTrials.gov Identifier: NCT04903288
(mai2025framelessintraputaminaldelivery pages 1-2): Roni Mai, Dmitriy Reshchikov, Vladimir Popov, Sergey Gorelikov, Ekaterina Zakharova, and Svetlana Mikhaylova. Frameless intraputaminal delivery of gene therapy with eladocagene exuparvovec in patients with aromatic l-amino acid decarboxylase deficiency: safe and efficient results. Child's Nervous System, Nov 2025. URL: https://doi.org/10.1007/s00381-025-07020-y, doi:10.1007/s00381-025-07020-y. This article has 1 citations.
(deng2025centralbiogenicamine pages 1-2): Isaac Bul Deng, Jordan Follett, Jesse D. Fox, Shannon Wall, and Matthew J. Farrer. Central biogenic amine deficiency with concomitant exploratory behavioral deficits in dnajc12 knock-out mice. NPJ Parkinson's Disease, May 2025. URL: https://doi.org/10.1038/s41531-025-00991-4, doi:10.1038/s41531-025-00991-4. This article has 2 citations and is from a domain leading peer-reviewed journal.
(deng2024dnajc12inmonoamine pages 1-5): Isaac Bul Deng, Jordan Follett, Mengfei Bu, and Matthew J. Farrer. Dnajc12 in monoamine metabolism, neurodevelopment, and neurodegeneration. Movement Disorders, 39:249-258, Nov 2024. URL: https://doi.org/10.1002/mds.29677, doi:10.1002/mds.29677. This article has 17 citations and is from a highest quality peer-reviewed journal.
(sentieri2023analisideilivelli pages 21-25): E Sentieri. Analisi dei livelli di 3-omd su dbs nella popolazione neonatale ligure: verso lo screening di aadcd. Unknown journal, 2023.
(lee2024apositionstatement pages 1-2): Hui-Min Lee, Saadet Mercimek-Andrews, Gabriella Horvath, Diana Marchese, Richard E. Poulin, Alexis Krolick, Kati-Lyn Tierney, Jasmine Turna, Judy Wei, and Wuh-Liang Hwu. A position statement on the post gene-therapy rehabilitation of aromatic i-amino acid decarboxylase deficiency patients. Orphanet Journal of Rare Diseases, Jan 2024. URL: https://doi.org/10.1186/s13023-024-03019-x, doi:10.1186/s13023-024-03019-x. This article has 10 citations and is from a peer-reviewed journal.
(roubertie2024genetherapyfor media e0e2cf3d): Agathe Roubertie, Thomas Opladen, Heiko Brennenstuhl, Oya Kuseyri Hübschmann, Lisa Flint, Michel A. Willemsen, Vincenzo Leuzzi, Angels Garcia Cazorla, Manju A. Kurian, Marie Céline François‐Heude, Paul Hwu, Bruria Ben Zeev, Karl Kiening, Thomas Roujeau, Roser Pons, and Toni S. Pearson. Gene therapy for aromatic l‐amino acid decarboxylase deficiency: requirements for safe application and knowledge‐generating follow‐up. Journal of Inherited Metabolic Disease, 47:463-475, Jul 2024. URL: https://doi.org/10.1002/jimd.12649, doi:10.1002/jimd.12649. This article has 27 citations and is from a peer-reviewed journal.
(deng2025centralbiogenicamine pages 2-4): Isaac Bul Deng, Jordan Follett, Jesse D. Fox, Shannon Wall, and Matthew J. Farrer. Central biogenic amine deficiency with concomitant exploratory behavioral deficits in dnajc12 knock-out mice. NPJ Parkinson's Disease, May 2025. URL: https://doi.org/10.1038/s41531-025-00991-4, doi:10.1038/s41531-025-00991-4. This article has 2 citations and is from a domain leading peer-reviewed journal.
(roubertie2024genetherapyfor pages 4-4): Agathe Roubertie, Thomas Opladen, Heiko Brennenstuhl, Oya Kuseyri Hübschmann, Lisa Flint, Michel A. Willemsen, Vincenzo Leuzzi, Angels Garcia Cazorla, Manju A. Kurian, Marie Céline François‐Heude, Paul Hwu, Bruria Ben Zeev, Karl Kiening, Thomas Roujeau, Roser Pons, and Toni S. Pearson. Gene therapy for aromatic l‐amino acid decarboxylase deficiency: requirements for safe application and knowledge‐generating follow‐up. Journal of Inherited Metabolic Disease, 47:463-475, Jul 2024. URL: https://doi.org/10.1002/jimd.12649, doi:10.1002/jimd.12649. This article has 27 citations and is from a peer-reviewed journal.
(roubertie2024genetherapyfor media d99c2658): Agathe Roubertie, Thomas Opladen, Heiko Brennenstuhl, Oya Kuseyri Hübschmann, Lisa Flint, Michel A. Willemsen, Vincenzo Leuzzi, Angels Garcia Cazorla, Manju A. Kurian, Marie Céline François‐Heude, Paul Hwu, Bruria Ben Zeev, Karl Kiening, Thomas Roujeau, Roser Pons, and Toni S. Pearson. Gene therapy for aromatic l‐amino acid decarboxylase deficiency: requirements for safe application and knowledge‐generating follow‐up. Journal of Inherited Metabolic Disease, 47:463-475, Jul 2024. URL: https://doi.org/10.1002/jimd.12649, doi:10.1002/jimd.12649. This article has 27 citations and is from a peer-reviewed journal.
(kulhanek2026studyofdiagnostica pages 46-49): J Kulhánek. Study of diagnostic and clinical aspects of selected inherited metabolic diseases. Unknown journal, 2026.
(roubertie2024genetherapyfor pages 3-3): Agathe Roubertie, Thomas Opladen, Heiko Brennenstuhl, Oya Kuseyri Hübschmann, Lisa Flint, Michel A. Willemsen, Vincenzo Leuzzi, Angels Garcia Cazorla, Manju A. Kurian, Marie Céline François‐Heude, Paul Hwu, Bruria Ben Zeev, Karl Kiening, Thomas Roujeau, Roser Pons, and Toni S. Pearson. Gene therapy for aromatic l‐amino acid decarboxylase deficiency: requirements for safe application and knowledge‐generating follow‐up. Journal of Inherited Metabolic Disease, 47:463-475, Jul 2024. URL: https://doi.org/10.1002/jimd.12649, doi:10.1002/jimd.12649. This article has 27 citations and is from a peer-reviewed journal.
(NCT05765981 chunk 1): An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.. Shanghai Jiao Tong University School of Medicine. 2023. ClinicalTrials.gov Identifier: NCT05765981
(NCT02852213 chunk 1): Krzysztof Bankiewicz. A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients. Krzysztof Bankiewicz. 2016. ClinicalTrials.gov Identifier: NCT02852213

Ask OpenScientist

OpenScientist Report

Inheritance

Subtypes

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Treatments

Biochemical Markers

Clinical Trials

Source YAML

References & Deep Research

Deep Research

1. Disease Information

1.1 Concise overview

1.2 Synonyms / alternative names (examples)

1.3 Evidence provenance

2. Etiology

2.1 Disease causal factors (primary)

2.2 Risk factors

2.3 Protective factors

2.4 Gene–environment interactions

3. Phenotypes (clinical features)

3.1 Cross-cutting phenotype patterns

3.2 AADC (DDC) deficiency phenotypes and onset

3.3 TH deficiency phenotypes and onset

3.4 BH4 deficiency disorders (group) phenotypes

3.5 Suggested HPO terms (non-exhaustive)

4. Genetic/Molecular Information

4.1 Causal genes (core set supported in retrieved evidence)

4.2 Pathway and biochemical roles (key concepts)

4.3 DNAJC12 mechanistic insight (model organism + human phenotype)

4.4 Suggested GO and CL terms (non-exhaustive)

5. Environmental Information

6. Mechanism / Pathophysiology

6.1 Causal chain (AADC deficiency as exemplar)

6.2 Key biochemical abnormalities and biomarkers

6.3 Gene therapy mechanism (AADC)

7. Anatomical Structures Affected

7.1 Primary systems

7.2 Key neuroanatomical targets in therapy/biomarkers

8. Temporal Development

8.1 Onset

8.2 Progression/course

9. Inheritance and Population

9.1 Inheritance patterns

9.2 Epidemiology highlights (recent evidence)

10. Diagnostics

10.1 Core diagnostic approach (umbrella)

10.2 AADC deficiency biomarkers (recommended)

10.3 TH deficiency diagnostics

10.4 Differential diagnosis (high level)

11. Outcome / Prognosis

11.1 Prognosis without disease-modifying therapy

11.2 Gene therapy outcomes in AADC deficiency

12. Treatment

12.1 Pharmacotherapy (supportive/symptomatic and pathway-based)

12.2 Disease-modifying therapy: AADC gene therapy (eladocagene exuparvovec)

12.3 Clinical trials (selected; gene therapy)

12.4 Suggested MAXO terms (examples)

13. Prevention

13.1 Secondary prevention: newborn screening

14. Other Species / Natural Disease

15. Model Organisms

Key concepts and definitions (consolidated)

Recent developments and real-world implementation highlights (2023–2024 prioritized)

Statistics and data (recent studies)

Evidence-backed abstract quotes (selected)

Visual evidence (pathway and vector schematic)

Structured gene/phenotype scaffold

Key evidence gaps (explicit)